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- Abstract -  
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Mucus covers our inner interfaces towards the environment, providing protection while enabling 
vital interaction with the outside world. The mucus is built around mucin proteins, which are 
important for our defences against infection and inflammation, but may also contribute to 
carcinogenesis and tumour progression. These divergent aspects of mucin biology are exemplified 
in the different studies in this thesis, which are all based on mass spectrometry. The topics covered 
range from mucin biomarkers for the early diagnosis of pancreatic cancer, to the discovery of a link 
between a mucus-associated bacterial genus and irritable bowel syndrome. 
Pancreatic cancer is a relatively rare tumour form, but is postulated to become the second 
leading cause of cancer deaths in the United States by 2030. The poor prognosis is largely explained 
by late detection. With advances in imaging, cystic precursors of pancreatic cancer are detected with 
increasing frequency, offering an unprecedented opportunity for prevention and cure. Unfortunately, 
available diagnostic tools are not sufficiently robust to enable targeted intervention against high-risk 
cystic lesions. Here, we describe the development and evaluation of a mass spectrometry based 
method for quantification of mucins and other biomarkers in pancreatic cyst fluid samples. In a 
prospective validation cohort, the analysis identified cystic precursors of pancreatic cancer with 
97% accuracy. This result represented a significant improvement upon state-of-the-art diagnostic 
methods. Thus, clinical implementation of the analysis may facilitate early detection of pancreatic 
cancer, which is a prerequisite for increasing survival rates. 
Ulcerative colitis is an inflammatory bowel disease with a chronic and relapsing course. 
According to the current view, ulcerative colitis results from inappropriate interactions between 
colonic microbiota and host immunity, against a background of genetic susceptibility. Normally, the 
abundant luminal microbes are segregated from the colonic epithelium, through an impervious 
mucus barrier. Here, abnormalities in mucus protein composition were detected in ulcerative colitis 
patients, also in samples from non-inflamed areas. This implies that structural weakening of the 
colonic mucus barrier could be important for the development of the disease.  
The natural history of ulcerative colitis varies considerably between patients. Prognostic 
markers for the disease course could reduce relapses and colectomies, as well as the unnecessary 
use of medication. Herein, we identified a ratio of two proteins in colonic mucus as a powerful 
predictor of the requirement for intensified medication or surgery during a five year period. 
Interestingly, these two proteins differentially regulate the sensing of specific microbial ligands. An 
altered equilibrium of these proteins was tentatively associated with infiltration of bacterial 
endospores in the colonic lamina propria. Thus, intermittent activation of endospores may 
conceivably contribute to relapses in patients with severe ulcerative colitis.  
Brachyspira is a bacterial genus that includes several pathogenic species. In this thesis, 
Brachyspira colonization of the colonic epithelial surface and inner mucus layer was detected in one 
third of IBS patients, but rarely observed in healthy individuals. Furthermore, Brachyspira 
colonization was associated with a distinctive symptom profile and mucosal immune response. This 
suggests that targeted antibiotic therapy of this patient group may reduce the morbidity burden of 
IBS. However, in our investigation antibiotic treatment paradoxically resulted in Brachyspira 
invasion of goblet cell mucus granules. This observation may represent a novel bacterial strategy to 
evade and survive antibiotic treatment, with potential, broad implications for our understanding of 
therapy resistant infections and pathogen persistence in the intestinal reservoir.  
Keywords: Mucus, mass spectrometry, MUC2, MUC5AC, IPMN, pancreatic cysts, ulcerative 
colitis, IBS, Brachyspira 
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 SAMMANFATTNING PÅ SVENSKA 
Medan utsidan av vår kropp är täckt av hud, skyddas insidan av våra luftvägar, tarmar och urinvägar 
av ett slemlager. Detta lager är uppbyggt av särskilda proteiner som kallas muciner. Muciner är 
viktiga för vårt försvar mot infektion och inflammation, men kan också i vissa fall bidra till 
uppkomsten av cancer. I denna avhandling beskrivs hur muciner och andra proteiner i slemlagret 
påverkar olika aspekter av hälsa och sjukdom i magtarm-kanalen. Fynden omfattar bland annat hur 
muciner kan fungera som biomarkörer för tidig bukspottskörtelcancer, hur ett försvagat slemlager 
kan bidra till tarmsjukdomen ulcerös kolit, och en ny koppling mellan förekomsten av ett särskilt 
bakteriesläkte i slemlagret och IBS (irritable bowel syndrome).  
Cancer i bukspottskörteln diagnosticeras ofta i ett sent stadium, och överlevnaden är därför 
mycket låg. Cystiska (vätskefyllda) förstadier till bukspottskörtelcancer kan upptäckas med 
skiktröntgen och magnetkameraundersökning, men är svåra att skilja från godartade cystor. I 
avhandlingen presenteras en ny metod för att identifiera cystiska förstadier till 
bukspottskörtelcancer. Analysen utförs på cystvätskeprover. Dessa tas vid en endoskopisk 
undersökning som används rutinmässigt i sjukvården.  Metoden innebär att nivåerna av vissa 
muciner och andra proteiner mäts i cystvätskan med hjälp av masspektrometri. Med denna teknik 
kunde cystiska förstadier till bukspottskörtelcancer upptäckas med 97 % säkerhet, vilket var 
signifikant bättre än resultaten för de diagnostiska metoder som används idag. Sammantaget skulle 
införandet av analysen i sjukvården potentiellt kunna leda till fler fall av tidig upptäckt av 
bukspottskörtelcancer, vilket är centralt för att förbättra överlevnaden.  
Ulcerös kolit är en kronisk inflammatorisk tarmsjukdom, med omväxlande skov av aktivitet 
och symptomfria perioder. Orsaken till sjukdomen är okänd, men tros bero på ett avvikande 
immunsvar mot den normala bakteriefloran i tarmen. Normalt sett skyddas insidan av tarmen av ett 
tjockt, ogenomträngligt slemlager. Här visar vi att försvagning av detta slemlager föregår 
inflammationen, och därigenom skulle kunna bidra till sjukdomens uppkomst. Förloppet av ulcerös 
kolit varierar påtagligt mellan individer. Metoder för att förutspå sjukdomsaktiviteten skulle kunna 
förbättra behandlingen för den enskilda patienten. I avhandlingen presenteras två biomarkörer som 
kunde förutsäga behovet av ökad medicinering och kirurgi under en femårsperiod med nästan 90 % 
säkerhet. Dessa två proteiner reglerar slemhinnans immunsvar mot vissa bakterier, varför vi också 
studerade bakterieförekomsten i vävnaden. Vi noterade då en tänkbar koppling mellan täta och 
svåra skov och fynd av bakteriella sporer i slemhinnan. Genom sporbildning kan bakterier överleva 
under lång tid och svåra förhållanden. Re-aktivering av sporer i tarmvävnaden skulle potentiellt 
kunna utlösa skov av ulcerös kolit, även om detta måste studeras vidare.  
Var femte till var tionde person är drabbad av IBS. I denna avhandling påvisas en koppling 
mellan IBS och Brachyspira – ett bakteriellt släkte som innehåller flera sjukdomsalstrande arter. 
Brachyspira koloniserade tarmcellernas yta hos en femtedel av alla IBS-patienter som undersöktes i 
studien. Motsvarande fynd sågs inte hos några friska personer. Växt av Brachyspira på 
tarmcellsytan var kopplat till diarré, snabb tarmpassage, inflammation och aktivering av mastceller. 
Det har tidigare visats att mastceller utsöndrar substanser som påverkar tarmens smärtkänslighet vid 
IBS. Behandling med antibiotika ledde till förbättring av symptomen, men utrotade inte infektionen. 
Istället noterades att Brachyspira hittat en ny nisch inuti tarmens bägarceller. Sammantaget visar 
våra fynd på en potentiellt botbar orsak hos en hög andel individer med IBS. Invasionen av 
bägarceller efter antibiotika motsvarar en ny mekanism för bakterier att överleva 
antibiotikabehandling. Detta fynd skulle kunna ha en övergripande betydelse för vår förståelse av 
svårbehandlade och återkommande infektioner.  
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1 INTRODUCTION 
This thesis encompasses three disorders of the gastrointestinal tract: pancreatic cystic 
tumours, inflammatory bowel disease and irritable bowel syndrome. Not only do these 
conditions affect two different organs, they also represent three traditionally distinctive 
categories of gastrointestinal diseases: neoplastic, inflammatory and functional. 
Pancreatic cystic tumours and irritable bowel syndrome are about equally common, but 
differ fundamentally in other ways. One affects the elderly, the other the young. One is 
associated with findings, the other with symptoms. Finally, pancreatic cancer has the 
highest and irritable bowel syndrome the lowest mortality among the major 
gastrointestinal diseases. However, all three conditions share one frustrating and 
compelling characteristic: they are poorly understood. 
Hence, the studies in this thesis may appear very disparate. Nevertheless, while the 
organs and disorders may be different, the cells and molecules of interest are much 
more similar. This investigation is based on mass spectrometry analyses of mucus-
resident proteins, hopefully demonstrating some of the versatility of this technique. 
Mucus and its integral components, mucins, are produced by specialized cells. Mucins 
are important in infection, inflammation and cancer, both to our benefit and our 
detriment. Aberrant expression of the MUC1 mucin is postulated to contribute to 
nearly two thirds of cancer cases in the United States. On the other hand, the MUC2 
mucin protects the inside of our intestines from inflammation and colon cancer 
development. 
The abundant gut microbiota influences our gastrointestinal, metabolic and even 
mental health. Importantly, mucus is the arena where the intestinal microbiota and the 
host meet, and proteins the main functional tools through which they interact. Thus, 
further studies of the gastrointestinal mucus proteins, both human and microbial, could 
potentially contribute to our understanding of other disorders –that may appear more 
unrelated than those investigated in this thesis.  
1.1 PROTEOMICS AND MASS SPECTROMETRY 
Proteomics is the study of the proteome; a synthesis of the words “protein” and 
“genome”.1 The proteome refers to the full set of proteins identified in a system, such 
as a tissue or a biological fluid. However, in contrast to the genome, the proteome is 
dynamic and alters over time, and with varying requirements of the cell, tissue or 
organism. The properties of proteins may also be influenced by various post-
translational modifications, such as glycosylation and phosphorylation of particular 
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amino acids. Thus, the proteome represents an ideal source of disease-specific 
biomarkers.  
Although proteomics was originally a generic term for all studies of protein expression, 
including for example antibody-based approaches, nowadays it usually refers to the 
analysis of proteins by mass spectrometry (MS). While it is possible to analyse full 
proteins by mass spectrometry (top-down proteomics), this technique is more time-
consuming and complicated than the analysis of a mixture of peptides (bottom-up 
proteomics).2 Hence, enzymatic digestion of proteins is generally part of the sample 
preparation for MS.  
1.1.1 Sample preparation 
The first step in the work-flow for proteomic analysis has traditionally been to reduce 
sample complexity, in order to aid the subsequent identification of proteins. Separation 
of proteins by their molecular mass, e.g. through a one-dimensional gel 
electrophoresis, is still a common strategy.  
In order for proteases (i.e., “protein-cleaving” enzymes) to gain access to the protein 
backbone, proteins must first be solubilized and denatured. This is achieved through 
the addition of a chaotropic agent such as urea or guanidine hydrochloride. Disulphide 
bonds (between cysteine residues) that are stabilizing the protein, are typically broken 
by reduction (e.g. through dithiothreitol) and prevented from reforming by alkylation 
(e.g. through iodoacetamide). The break-down of the three-dimensional conformation 
of the protein allows proteases to digest it. The most commonly used protease in 
proteomic studies is the pancreatic enzyme trypsin. It is very important that the 
protease used is specific, i.e., cleaves the amino acid chain in a predictable manner. 
Trypsin, for instance, cleaves the peptide backbone at the carboxyl side of amino acids 
arginine (R) and lysine (K), unless they are followed by a proline (P). Multiple libraries 
of peptides that can theoretically be produced through the digestion of a particular 
protein with a particular protease have been generated, and are used for peptide and 
protein identification. 
1.1.2 Liquid chromatography 
In order to enhance the sensitivity of the MS analysis, prior separation of peptides 
through liquid chromatography (LC) is a common practice. There are various LC 
methods, suited to different sample types and downstream applications. However, the 
fundamental principle involves the separation of peptides according to their chemical 
or physical properties, based on their passage through a system. Typically, this system 
consists of a column packed with an adsorbent material, known as the “stationary 
phase”.3 The interaction of the sample with the stationary phase is affected by a third, 
liquid component: the “mobile phase”. The composition of this liquid may be altered in 
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a controlled manner during the course of the experiment. Commonly, the mobile phase 
consists of a mixture of polar and non-polar components, where the concentration of 
the organic solvent is gradually increased or decreased. Thus, peptides will elute from 
the column at different time points, based on their hydrophobicity. Online LC-MS 
systems, with direct coupling between the LC unit and the mass analyser are nowadays 
frequent.  
1.1.3 Mass spectrometry 
Briefly, a mass spectrometer consists of three parts: an ionizer, a mass analyser and a 
detector. First, the peptides are ionized, which is prerequisite for mass analysis and 
detection. For proteomics, “soft” ionization techniques like electrospray ionization 
(ESI) are typically favoured. ESI, which was used for the studies included in this 
thesis, is capable of the generation of ions with multiple charges. This allows for the 
acquisition of mass to charge (m/z) spectra also from relatively large molecules. 
Analysis in positive or negative ion mode is possible, although the former is more 
common.4 During ESI, the peptide ions are contained in minuscule droplets. In positive 
ion mode analysis, the liquid of these droplets is acidic. This means that the basic 
amino acids of a peptide, as well as its N-terminus, will be protonated. Trypsin cleaves 
the peptide backbone after arginine and lysine, which are both basic amino acids. 
Therefore, each tryptic fragment will have a charge of at least 2+. Non-peptide 
compounds in the sample can be distinguished from the actual peptides, since they are 
usually singly charged.  
Following ionization, the sample enters the mass analyser. The mucin profiling of 
pancreatic cyst fluid in Paper I, was done with a Fourier-transform ion cyclotron 
resonance mass analyser, wherein the movement of ions in a magnetic field is used to 
deduce their m/z ratio.5 In the Orbitrap mass analyser used in papers II-V of this thesis, 
ions oscillate around a central, spindle-shaped electrode and between two outer cup-
shaped electrodes, along a defined axis.6 Again, their oscillation frequency is directly 
dependent on their mass. In tandem mass spectrometry (MS/MS), following analysis of 
the full peptide, fragments are also generated. Usually, fragmentation is achieved 
through collision of the peptides with neutral atoms/molecules (e.g. nitrogen) in gas 
phase. The peptide fragments will then again enter a mass analyser, where their 
individual m/z values will be determined. The rationale for this procedure is to 
facilitate peptide sequence identification. The role of the detector is to register the 
oscillation frequency and intensity of the ions. Simply put, the intensity is determined 
by how frequently the signal from a particular ion is registered by the detector, over an 
observation period. For both examples of mass analysers, the recorded image current is 
translated into a spectrum of mass to charge ratio (x-axis) and intensity (y-axis) values, 
through a Fourier transform function. 
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1.1.4 Identification of peptides and proteins  
The basis for peptide and protein identification is the comparison of masses and 
MS/MS fragmentation spectra from the experiment, with theoretical results from “in 
silico” digested proteins. Specialized software and databases, nowadays available for 
many different organisms, are used for this procedure. In order to estimate the 
frequency of false positive results (the false discovery rate), a parallel search is 
performed against a decoy database. The decoy database is generally constructed by 
reversing the amino acid sequences from the original database. A threshold of a 
minimum of one unique peptide at a false discovery rate of 1%, is typically applied for 
protein identification.7 However, in certain situations more stringent criteria may be 
appropriate. 
1.1.5 Relative and absolute protein quantification  
One major drawback of proteomic analysis by MS is that the technique is not 
inherently quantitative. The intensity measured for a peptide does not directly reflect 
its abundance. It is also dependent on its chemical properties, which will, for instance, 
affect ionization efficiency. Relative quantification may be achieved through chemical 
labelling (isotopic/isobaric) or through so-called label-free quantification.8The latter 
involves the comparison of protein abundances between samples through the frequency 
with which a certain peptide is detected, as well as the intensity of the same peptide, as 
recorded by the detector. With label-free quantification, variations in sample 
processing and analysis must be kept to a minimum so as not to introduce bias. 
Absolute quantification is possible through the selection of a peptide mass or a peptide-
fragment-ion pair for analysis through e.g. Selected/Single Ion Monitoring (SIM) or 
Selected Reaction Monitoring (SRM).9,10 Instrument parameters can then be set to 
exclude other m/z values. The introduction of an internal standard, in the form of a 
known quantity of a labelled custom-designed synthetic peptide, corresponding to the 
target of interest, makes it possible to determine the exact concentration of a protein in 
a sample. 
1.1.6 Metaproteomics 
Metagenomics, the study of the entire repertoire of genes found in environmental 
samples, has revolutionized the study of microbial communities. Unlike culture-based 
approaches, metagenomics enables high-throughput profiling of microbes in their 
natural habitat. By contrast, in metaproteomic studies, MS is used to study the full set 
of proteins from different organisms within a complex sample. Proteins, the functional 
product of genes, perform the majority of essential tasks in cells and organisms.  Even 
transcriptomic data do not correlate perfectly with protein expression.12 This means 
that meta-proteomic studies could potentially provide a more accurate and 
comprehensive functional characterization of microbial communities. In summary, 
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genomic data informs us about which microbes are present in a sample, and what they 
are theoretically able to do. By contrast, metaproteomics could tell us what they are 
actually doing in that environment- for instance inside the human body. Within the last 
few years, metaproteomic studies have investigated the microbial communities of the 
oral cavity, the vagina and the gut.15-17 A few studies have also begun to address 
metaproteomic alterations associated with particular disorders, including inflammatory 
bowel disease.18,19  
While the sample preparation workflow is largely similar to standard mass 
spectrometry-based proteomics, the bioinformatics analysis poses formidable 
challenges. As an example, the human intestine could contain up to a thousand 
different species.20 Each of these express thousands of different proteins. Protein 
homology between species, horizontal gene transfer and strain variation add to the 
complexity of the analysis.21 Thus, the identification and taxonomic annotation of 
peptides during metaproteomic analysis places a great strain on both hardware and 
software. Moreover, only a small minority of the global microbial community has been 
sequenced.22 As of 2014, 30,000 bacterial genome sequences were publically available 
- while the number of bacterial species on Earth has been estimated to exceed one 
trillion.22    
1.2 MUCINS AND CANCER 
Mucins are a family of high-molecular mass, heavily glycosylated glycoproteins 
characterized by typical domains rich in the amino acids proline, threonine and serine. 
The serine and threonine residues are frequently O-glycosylated, giving the protein a 
“bottle-brush-like” appearance. As a result, over half of the mass of the protein is 
accounted for by glycans.23,24 Mucins may be transmembrane (such as MUC1 and 
MUC4) or secreted (such as MUC2, MUC5AC and MUC6). Both forms are important 
for the protection of the apical surface of epithelial cells.23,24 Secreted mucins form a 
gel that lubricates the epithelium and shields it from environmental hazards such as 
HCl in the ventricle and bacteria in the colon. Transmembrane mucins also provide 
physical protection. In addition, they are likely important for the cell´s sensing of the 
external environment.23,24 
1.2.1 Role in cancer  
Both transmembrane and secreted mucins have been reported to be overexpressed, or 
aberrantly expressed, in malignancies. The role of mucin-1 (MUC1) in epithelial 
cancers has been particularly well elucidated. In fact, 64% of the cancers diagnosed in 
the United States each year are estimated to exhibit overexpression or de novo 
expression of MUC1.25 
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Loss of polarity in cancer leads to expression of transmembrane mucins on the 
basolateral side of the cells, enabling their interaction with e.g. receptor tyrosine 
kinases.23-24 This phenomenon has been shown to activate signalling pathways 
associated with cell proliferation and survival. For instance, studies indicate that 
MUC1 promotes EGFR signaling in cancer cells.23-26 Aberrant expression of secreted 
mucins may favour tumour progression by “hiding” the neoplastic cells from innate 
immunity.27,28 In pancreatic ductal adenocarcinoma, de novo expression of the gel-
forming MUC5AC is an early event, occurring in both micro- and macroscopic 
precursor lesions.28-30 
1.3 PANCREATIC CYSTIC TUMOURS 
The incidence of pancreatic cystic tumours has increased dramatically during the last 
three decades.31,32 This is likely due to a combination of two factors: increased 
detection, as a result of advances in the quality and availability of imaging techniques, 
and greater awareness and understanding of these conditions. In fact, the most common 
form of pancreatic cystic tumour, intraductal papillary mucinous neoplasm (IPMN) 
was recognized as a clinical entity less than 40 years ago.33  
Pancreatic cystic lesions are very common incidental findings on imaging, identifiable 
on 2.6% of abdominal computed tomography (CT) scans.34 Using  magnetic resonance 
imaging (MRI), a prevalence of nearly 50% was established in a population-based 
study of mostly middle-aged participants (mean age 55).35  Until relatively recently, 
over 90% of incidentally detected cystic lesions were believed to be inflammatory 
pseudocysts. However, several studies indicate that the majority are actually cystic 
tumours. Furthermore, most of these tumours are now considered to have malignant 
potential.31,36 
Pancreatic cystic neoplasms form a heterogenous group with regard to clinical 
presentation and prognosis. The most common pancreatic cystic tumours are serous 
cystic neoplasms, mucinous cystic neoplasms (MCN), intraductal papillary mucinous 
neoplasms (IPMN) and cyst-like ductal adenocarcinomas, while solid pseudopapillary 
neoplasms and cystic endocrine tumors are rare entities.  Of all these tumour types, 
only serous cystic neoplasms are considered completely benign. At the other end of the 
spectrum, cyst-like ductal adenocarcinomas have the same dismal prognosis as solid 
exocrine pancreatic cancer.31,37,38 IPMN, and MCN have malignant potential.31,37,38 
However, only a minority are malignant at the time of diagnosis and malignant 
progression is thought to occur over several years, perhaps even decades.39,40 
Nevertheless, these tumours are nowadays recognized as precursors to ductal 
adenocarcinoma.29,41 Thus, they can be considered macroscopic counterparts of 
pancreatic intraepithelial neoplasia (PanIN), from which all exocrine pancreatic 
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cancers were previously thought to derive. This insight has offered an unprecedented 
opportunity for early, or even preventive, intervention against pancreatic cancer. Early 
diagnosis is pivotal in order to improve the outcome of pancreatic cancer, which at 
present is almost always discovered at a stage where it has already metastasized to 
other organs. Consequently, the prognosis has remained very poor, with 5-year survival 
rates lingering around 8%.42 
From their respective prevalence figures, it is obvious that most pancreatic cystic 
lesions will never progress to pancreatic cancer. Resection of a pancreatic cystic lesion, 
particularly in the head of the pancreas, involves major surgery with a relatively high 
risk of complications.32 Thus, accurate diagnosis, and a careful selection of surgical 
candidates is of paramount importance. Consensus guidelines for the management of 
different pancreatic cystic tumour types are available.37,38,43 However, at present a 
definitive diagnosis is rarely possible before surgery.44,45 
1.3.1 Pathophysiology 
The pathogenesis of pancreatic cystic neoplasms varies with tumour type, but is 
generally relatively poorly understood.  
Figure 1. Macroscopic images of a resected IPMN in the head of the pancreas. Image courtesy 
of Professor Caroline Verbeke, University of Oslo 
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Serous cystic neoplasms affect predominantly females, typically present as a 
conglomerate of small cystic lesions, and are frequently detected in patients with Von 
Hippel Lindau syndrome.31,46 Von Hippel Lindau´s disease is caused by mutation of the 
VHL gene, which encodes a protein that negatively regulates the expression of 
Hypoxia Inducible Factor 1 alpha (HIF1α). In the absence of a functional VHL protein, 
HIF1α will activate the transcription of a set of genes, including vascular endothelial 
growth factor, erythropoietin and several genes associated with the uptake and 
metabolism of glucose. These aberrations are consistent with the morphology of serous 
cystic neoplasms, which are characterized by glycogen accumulation and 
hypervascularization.47  
Mucinous cystic neoplasms (MCN) resemble serous cystic neoplasms in that they 
affect almost exclusively women (>95%), while they share mucinous content and 
malignant potential with IPMN.47,48 Morphologically, MCN are macrocystic or 
unilocular lesions, usually located in the tail of the pancreas.31,37,38 Unlike IPMN, they 
have no connection with the pancreatic ducts. Histologically, MCN consist of two 
components: a columnar cell mucin-producing epithelium and an “ovarian-like” stroma 
with estrogen and progesterone receptors.47 Taken together, the predilection of MCN 
Figure 2. Microscopic image of an IPMN. Courtesy of Professor Caroline Verbeke, University 
of Oslo. 
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for females, the fact that most cases occur in the “perimenopausal” period (mean age 
48) and the presence of ovarian-type stroma, strongly suggest that hormonal factors are 
involved in the pathogenesis of the tumour.31,47 Studies indicate that KRAS is 
frequently activated in MCN with intermediate or high grade dysplasia. Moreover, 
mutations resemble the spectrum observed in ductal adenocarcinoma.49 However, the 
exact mechanisms underlying the development of an MCN have remained enigmatic. 
IPMN per definition involve the pancreatic ductal system; the main duct, the branch 
ducts or both. Tumours that are limited to the branch ducts have a better prognosis than 
those that involve the main pancreatic duct.31,37,38 IPMN can also be categorized based 
on their epithelium and mucin expression, with prognostic implications.50,51 However, 
classification of IPMN according to the latter features has rarely been possible before 
surgery. 
Like ductal adenocarcinomas and MCN, IPMN often harbour activating KRAS 
mutations.49,52 By contrast, GNAS mutations appear to be characteristic of IPMN, 
although present in only two thirds of cases.52 Activation of GNAS results in cAMP 
production and activation of protein kinase A.53 GNAS mutations  may also affect 
mucin expression.54  Furthermore, in a whole-exome sequencing study, inactivating 
mutations of the gene encoding for an E3 ubiquitin ligase, RNF43, were found to be 
common in IPMN.55 The role of this protein is to “select” other proteins for 
proteosomal degradation. The full spectrum of proteins ubiquitinated by RNF43 is not 
known. However, according to the current model, RNF43 acts as a tumor suppressor 
through the antagonism of Wnt signalling. Most likely, RNF4 inhibits oncogenic Wnt 
signaling by targeting its receptor, Frizzled, for degradation.56 
The microscopic PanIN and the macroscopic IPMN are the most common precursors 
of pancreatic cancer. The possibility of a common origin for these two precancerous 
conditions is a matter of debate. In fact, both lesions are fundamentally defined by size: 
PanIN are <5mm; IPMN >10mm.57 Thus, a large group of lesions falls between these 
two categories, and may be an interesting topic for future studies. Furthermore, patients 
with IPMN have an increased risk of developing pancreatic cancer from synchronous 
or metachronous microscopic precursors. This points to a “field defect” of acquired 
mutations or epigenetic alterations, which contribute to cancer development through 
both macroscopic and microscopic forerunners.31,58 
1.3.2 Diagnosis 
Pancreatic pseudocysts are usually observed in a setting of either acute or chronic 
pancreatitis. However, pancreatic cystic tumours, particularly IPMN, may also cause 
acute pancreatitis. Furthermore, main-duct IPMN can morphologically mimic chronic 
pancreatitis, since dilation of the main duct is a feature of both conditions.31  
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Commonly available imaging methods like computed tomography (CT) and magnetic 
resonance imaging (MRI) detect pancreatic cystic lesions with increasing frequency. 
However, they are usually not sufficient for their differential diagnosis.38,59-61  Studies 
indicate an overall diagnostic accuracy ranging from 40 to 80% for CT and MRI for 
the assessment of pancreatic cystic lesions, with no clear advantage for either 
method.38,59,60 Interestingly, even for cases where the radiologist reported feeling 
highly confident about the diagnosis, the accuracy was not substantially higher.59   
Endoscopic ultrasound (EUS) is a method for the visualization of inner organs adjacent 
to the esophagus, ventricle and duodenum. With this approach, interferences from the 
abdominal wall and intestinal gas (that limit the utility of external ultrasound for the 
assessment of pancreatic pathology) are avoided. Using an ultrasound device attached 
to a modified endoscope, the organ can be visualized with high resolution, superior to 
that of CT and MRI. Another advantage of the technique is that it allows for fine-
needle aspiration of cyst fluid for cytology, and quantification of the tumour marker 
CEA (carcinoembryonic antigen). Drawbacks are the facts that it is invasive, and 
highly dependent on the skills and the experience of the observer.  
Despite the high resolution, EUS accuracy for the differential diagnosis of pancreatic 
cystic lesions can still not be considered satisfactory, even when complemented with 
fine-needle aspiration.62 Cytology may result in a diagnosis, but the yield is often 
Figure 3. Schematic representation of the endoscopic ultrasound examination. Fine -
needle aspiration of pancreatic cyst fluid may be performed during the diagnostic 
procedure. Image adapted from Nassour I, Choti MA. JAMA. 2016; 316(12):1326., with 
the permission of the publisher. 
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scant.63-65 Atypia in cystic lesions is typically focal, and may easily be missed.47,63 
Furthermore, cystic tumours often contain areas of denuded epithelium which could 
lead to a false diagnosis of a pseudocyst, even in the histological examination.47 
Cyst fluid CEA is widely considered as a state-of-the art method for the identification 
of cystic precursors of pancreatic cancer (MCN and IPMN) with a reported diagnostic 
accuracy of 79%. However, in spite of more than 15 years of clinical use, there is still 
no established consensus on threshold levels for malignant potential. CEA levels also 
do not correlate with the degree of dysplasia and are not considered useful for the 
detection of malignant progression.38,62,65  
Molecular analysis of cyst fluid, targeting genomic alterations such as KRAS 
mutations, has been performed and evaluated in several studies.49,66 So far, these 
methods have not been conclusively shown to improve upon available diagnostic 
tools.66 However, recently, targeted next generation sequencing of KRAS/GNAS and 
TP53/PIK3CA/PTEN in cyst fluid was demonstrated to have high accuracy for the 
detection of premalignant and malignant pancreatic lesions, respectively.67 Still, MCN 
were frequently missed.67 One problem for genomic analysis in this context is that the 
cellular yield from cyst fluid samples tends to be very low.63-65  
Figure 4. Image of a serous cystic neoplasm acquired during endoscopic 
ultrasound examination. Multiple, dark-appearing cysts can be observed. The 
coloured segments represent blood vessels. Courtesy of Dr. Riadh Sadik. 
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There is also a growing number of proteomic and glycomic biomarker studies using 
pancreatic cyst fluid.68-71 However, the potential clinical utility of these markers 
remains uncertain, since these studies involved a laborious and time-consuming work-
flow, and/or reported on a small number of patients. Other novel approaches that await 
further validation include protease activity profiling, microRNA panels, DNA 
methylation, and metabolomic biomarkers.72-76 Interestingly, metabolomics identified 
cyst fluid glucose levels as an indicator of premalignant (mucinous) cystic lesions.76,77 
Such a test would have obvious appeal from a clinical viewpoint, due to the low costs 
and possibility of instant results. 
1.4 STRUCTURE AND FUNCTION OF THE COLONIC MUCUS LAYERS 
The colon extends from the caecum to the rectum, and is the site of fluid reabsorption, 
as well as microbial harvesting of energy from indigestible food components. Its inner 
(luminal) surface is very large in size, due to the presence of invaginations, referred to 
as crypts or glands. Further increasing the surface area, the luminal border of the 
colonocytes forms dense, finger-like projections, called microvilli. By contrast, the 
thickness of the epithelium corresponds to merely a single layer of columnar cells. This 
can be compared with the multi-layered, keratinized epithelium covering the external 
surface of our bodies. However, just like the skin, the colonic epithelium is constantly 
exposed to xenobiotics and other harmful substances. The colon is also much more 
densely colonized by microbes.  
Intestinal defence mechanisms against external threats include epithelial cell barrier 
integrity, primarily maintained through the intercellular tight junctions.78 The intestinal 
epithelial cells also express traditional innate immune recognition proteins, like Toll-
like receptors (TLRs) and Nod-like receptors (NLRs). This means that, like 
“professional” immune cells, they are able to recognize and respond to microbial 
ligands and motifs.79Another important protective factor is rapid cell turnover, where 
the colonic epithelium is largely renewed every few days.    
Nevertheless, these defences are not by themselves sufficient to cope with the 
formidable abundance and diversity of the colonic microbiota. In addition, a secreted, 
filter-like network built around the MUC2 mucin, shields the host from luminal 
bacteria, while still allowing us to benefit fully from their metabolic activities.80-83 
Importantly, the strict spatial segregation between the abundant colonic microbiota and 
the host also forestalls inappropriate immune reactions towards commensals and 
beneficial bacteria, which would otherwise result in chronic inflammation. The clinical 
significance of mucus protection has been demonstrated in Muc2-/- mice. These 
animals spontaneously develop severe colitis, and subsequently colon cancer.84,85 
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Similar findings have been observed in mice deficient in predominant Muc2 core O-
glycans.86,87 
MUC2 is produced by a distinctive cell type, known as goblet cells. Following 
translation and folding of the protein in the endoplasmic reticulum (ER), extensive O-
linked glycosylation occurs in the Golgi apparatus.88 The glycans are typically anionic, 
i.e., negatively charged. The rich glycosylation of secreted mucins is essential for their 
water-binding, and hence gel-forming, properties.83,88 
Subsequently, MUC2 is packed into goblet cell secretory granules in oligomeric form, 
having undergone C-terminal dimerization and N-terminal trimerization in the ER and 
Golgi, respectively.89,90 High concentrations of calcium and hydrogen ions 
(corresponding to a pH of about 5.2) inside granules favour a compact configuration of 
MUC2 oligomers.91 Following its release into the intestinal lumen, the MUC2 network 
expands about a 1000-fold. Concurrent bicarbonate secretion accomplishes the dual 
purposes of raising pH and precipitating calcium, enabling rapid and efficient 
unpacking of MUC2.91 Upon secretion, the MUC2 polymers organize into stratified 
sheets of hexagonal, ring-like structures.91 These hexagons represent “pores” in the 
mucus filter, which are further constricted through the formation of isopeptide 
bonds.92,93 Their size and configuration serve to restrict bacterial passage, vastly 
reducing epithelial exposure to microbes. 
The colonic mucus layer is in fact a two-tiered structure.80,83,88 The inner, adherent part 
is converted into a loose, permeable, outer layer at a distance from the epithelium, by 
endogenous proteases.80,83,88,94 The outer layer is densely colonized by microbes, which 
feed on the mucin glycans.80 The complex repertoire of the glycans attached to the 
MUC2 molecule suggest that these carbohydrates may have evolved to select for 
beneficial bacteria.83,88,95 Further illustrating the versatile roles of the mucus system in 
innate immunity, intestinal goblet cells are able to sample luminal microbial antigens 
or (in colon) even whole bacteria. These are then delivered to antigen-presenting cells 
in the underlying tissue.96,97 
Conversely, there is ample evidence that the gut microbiota regulates and influences 
the mucus system. Germ-free mice and rats have a more penetrable colonic inner 
mucus layer than their wild-type counterparts.98,99 However, long-term microbial 
colonization restored the imperviousness of the mucus barrier.99 Not only the presence, 
but also the composition of the colonic microbiota appears to influence mucus barrier 
properties. For instance, a high abundance of Proteobacteria was associated with 
increased penetrability of the inner mucus layer in mice.100 In humans, goblet cell 
numbers and mucus secretion are augmented during the Th2-mediated response to 
helminthic (worm) infections.101 However, microbiota can also directly induce goblet 
cell secretion, even in homeostatic conditions.102 Colonic upper crypt goblet cells 
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respond to microbial TLR ligands with a coordinated expulsion of mucus, orchestrated 
by a specialized cell population denoted as sentinel goblet cells.102 Thereby, microbes 
that have broken the host-microbial contract of mutualism and ventured too close are 
flushed away. 
1.5 GUT MICROBIOTA 
The human intestine is home to a complex ecological system of viruses, prokaryotes 
and micro-eukaryotes. Collectively, these organisms are referred to as the gut 
microbiota. Within an individual, the gut microbiota tends to outnumber the total 
amount of human cells, and accounts for a biomass of up to 1.5 kg.103 Over a thousand 
species have been identified from human intestinal samples, although the average 
colon is estimated to contain about 160 different species.20,104 Thus, there is 
considerable inter-individual variation, which is related to for example genetic, 
temporal, geographical and nutritional factors, as well as associated with health status 
and medication.105-108 Nevertheless, metagenomic studies have indicated that our 
intestines share a stable functional repertoire of microbial metabolic pathways.20,109 
The vast majority of the gut microbiota probably consists of bacteria. These can be 
subdivided into different phylogenetic, metabolic and functional groups. In addition, 
they are categorized in a practical way from a host perspective, into pathogens, 
commensals and beneficial bacteria.110 With the latter, we exist in a mutualistic 
relationship, profiting from their presence in various ways.111-113 The gut microbiota 
acts as a bioreactor, contributing to the degradation of nutrients ingested by the host, 
and producing a wide array of metabolites.112 Microbial products include vitamins like 
thiamin (B1), riboflavin (B2), pyrodoxin (B6), biotin (B7) and the vitamin K group.111 
Other important metabolites for the host are short chain fatty acids (SCFA). The most 
common SCFA are acetate, butyrate and propionate. These compounds provide up to 
10% of our caloric requirements, constitute the main energy source of the colonocytes, 
modulate intestinal motility and host inflammatory responses, and regulate 
proliferation, turnover and apoptosis of the colonic epithelial cells.112,114-118 The effects 
of microbial metabolite signaling are not limited to the intestines. Bacterial products 
have also been shown to influence distant organs, including adipose tissue, and the 
cardiovascular and central nervous systems.112,113,119-121 
Commensals are defined as microbes that “eat at the same table” as their host, 
implying that they don´t provide either substantial benefit or harm. However, 
commensals may in fact exert positive effects, by contributing to pathogen colonization 
resistance.122 This could occur through nutrient competition or modulation of the 
environment such that the expansion of pathogens is prevented.122-124 In addition, 
several species are able to secrete antibiotic substances (bacteriocins) that help 
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maintain intestinal microbial homeostasis.122,125 Moreover, beneficial and commensal 
bacteria are crucial for the development and education of the immune system.113,126-128  
According to the taxonomic terminology originating from the Linneaean system, 
bacteria are hierarchically subdivided into kingdom, phylum, class, order, family, 
genus and species. Five phyla predominate in the human intestine: Firmicutes, 
Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia.112 The two first 
are by far the most abundant.20,112,113,129 This division has traditionally been based on 
properties such as morphology, Gram staining and metabolism. However, the advent of 
molecular, culture independent, methods for bacterial identification has led to re-
classification of several species, as well as an upsurge in species detection.130 Recently, 
the introduction of high-throughput, low-cost methods for shotgun sequencing of the 
metagenome has enabled large-scale functional characterization of the gut microbiota 
in different conditions and disorders. 
However, in addition to inter-personal variation, there are large biogeographical 
differences within individuals. These render sampling issues critical. There is a 
longitudinal gradient, with microbial abundance and diversity increasing towards the 
distal (final) part of the intestinal tract.113,131 The richness and composition of the 
microbiota in different anatomical locations of the intestines is affected by transit time, 
pH, redox potential, as well as the presence of antimicrobial proteins and bile acids.131 
Moreover, there are cross-sectional differences, where luminal (faecal) bacteria differ 
from their mucus-associated counterparts.129,131,132 The outer, loose, mucus layer is 
richly colonized by bacterial species, some of which have the capacity to degrade the 
mucin glycans.80,,81,131,132 Other species simply possess the ability to scavenge and 
metabolize mucin sugar units, cleaved off by the former.133,134  
The colonic inner mucus layer is considered to be largely devoid of bacteria, and 
constitutes a physical barrier between the microbiota and the host.80,81 However, a 
small number of species have actually adapted to colonizing this niche. Previous 
studies have indicated the existence of a crypt-specific microbiome, largely composed 
of aerobes, such as Acinetobacter and Pseudomonas.135 Some bacteria are also able to 
directly colonize the epithelium, including segmented filamentous bacteria (SFB) in 
rodents, and Brachyspira in humans.136,137  
1.5.1 Brachyspira and intestinal spirochetosis 
Brachyspira belong to the Spirochaetes phylum, along with more illustrious pathogenic 
members, such as Borrelia (the causative agent of Lyme´s disease) and Treponema 
(syphilis). Spirochetes share the common characteristic of periplasmic flagella.138-140 
These are located not at the exterior of the bacterial cell, but between the inner and 
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outer membrane. The periplasmic flagella enable the elongated, spiral-shaped bacteria 
to propel themselves forward with a cork screw like motion.138-140 
Spirochetes, as well as bacteria in general and Brachyspira in particular, were first 
observed by Dutch microscopy pioneer Antonie van Leeuwenhook in the 17th 
century.140 He also appears to have been the first to recognize the pathogenic potential 
of Brachyspira, since he allegedly discovered them in his own diarrhoeal stool.141 
Unusually, to this day, microscopy has remained the standard way to diagnose 
Brachyspira infections (intestinal spirochetosis) in humans.137-140 The Brachyspira are 
highly fastidious, slow-growing anaerobes, which typically do not form colonies.138,139 
Thus, they are notoriously difficult to culture.138,139 However, in intestinal 
Figure 5. Intestinal spirochetosis in an IBS patient. Arrows indicate 
Brachyspira bacteria which form a characteristic, dense “fringe” on the 
epithelial surface. Image from a sigmoid colon section, stained by Alcian 
blue/PAS.  
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spirochetosis, they can be found in great density at the intestinal epithelial border, 
where they attach to the membrane in a perpendicular way.137-141 This produces a 
characteristic histological image, with a fringe of spirochetes on the epithelium, 
sometimes referred to as a “false brush border”.137-141Human-pathogenic Brachyspira 
can reach a length of 10 µm, and thus extend far beyond the microvilli (approximately 
1 µm long) into the intestinal lumen.138  
There are nine known Brachyspira species.138,140 All but one (aptly named B. innocens) 
of these, have pathogenic potential, although only two are postulated to cause disease 
in humans.137,138,140 Brachyspira are well-known pathogens in veterinary medicine, as 
the causative agents of swine dysentery and avian intestinal spirochetosis.138 B. 
pilosicoli is capable of infecting both humans and other species, including pigs, 
chicken and dogs.138 Thus, zoonotic transmission could potentially underlie a 
proportion of intestinal spirochetosis cases in humans. This may be particularly true for 
rural/peri-urban settings in developing countries, where high prevalences of 
Brachyspira colonization have been reported.142,143 By contrast, the second known 
human pathogen from the Brachyspira genus, B. aalborgi, is believed to be restricted 
Figure 6. Scanning electron micrograph of the colonic epithelial surface (top view). Brachyspira 
can be observed extending through the shorter, straight microvilli that protrude from the surface 
of the colonocytes. Image courtesy of Dr. Anna Ermund. 
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to primates.138-140 The existence of a third species causing intestinal spirochetosis has 
been suggested, but awaits further confirmation.137,144  
Although the concept of Brachyspira as a human pathogen dates back 400 years, it has 
remained controversial. On the one hand, there are numerous case reports linking 
Brachyspira to symptoms, including diarrhoea, abdominal pain, hemorrhagic stools, 
and even sepsis.145-149 Especially severe symptoms have been reported in pediatric 
disease.148,150,151 On the other hand, some observations argue against the importance of 
Brachyspira in human disease. In two studies, prevalence rates of Brachyspira in 
populations with gastroenteritis and chronic diarrhoea were reported to not differ from 
healthy controls.145,152 In contrast to segmented filamentous bacteria, Brachyspira 
infection does not typically elicit a strong local or systemic immune response.136, 138-140 
Furthermore, antibiotic treatment does not always led to full recovery, even though 
improvement of symptoms has been commonly described.145,146,150  
Overall prevalence rates of Brachyspira ranging between 0.5% and 3% have been 
reported from Europe, East Asia and Australia.145,151-155  However, studies of tissue 
specimens were generally performed in populations undergoing colonoscopy (or even 
colorectal resection) for clinical reasons. In a Swedish study, Brachyspira was detected 
Figure 7. Scanning electron micrograph showing a massive amount of Brachyspira extending 
from the colonic epithelial surface in an IBS patient. 
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in 2.2 % of individuals from a random population sample who accepted an offer of 
colonoscopy screening.154 Interestingly, 35% of persons diagnosed with intestinal 
spirochetosis in that study, also fulfilled criteria for irritable bowel syndrome (IBS).154 
This observation hints at an increased prevalence of spirochetosis in IBS patients. 
However, a potential association between Brachyspira and IBS has not been 
systematically investigated. 
1.6 IRRITABLE BOWEL SYNDROME 
The term “irritable” colon, later irritable bowel syndrome (IBS), was coined already in 
1915, replacing the earlier name “mucous colitis” (1892).156,157 However, the definition 
of this condition has continued to be revised and updated.158 According to the most 
recent designation, the Rome IV criteria of 2016, abdominal pain for at least one day 
per week during the last three months is a prerequisite for an IBS diagnosis.158 
Furthermore, two out of three additional criteria, indicative of a link between the pain 
and bowel habits, need to be fulfilled. The pain must either be directly related to 
defecation or associated with a change in stool frequency and/or consistency.158 Thus, 
abdominal pain is the unifying symptom in IBS patients who may have either 
predominant diarrhoea (IBS-D), constipation (IBS-C), or both (mixed-type IBS; IBS-
M), or neither (unsubtyped IBS; IBS-U).158,159  
Since IBS encompasses a wide range of abdominal symptoms, it is unlikely to be 
explained by one, sole mechanistic model. Moreover, IBS may, to a varying degree, be 
associated with a plethora of extra-colonic comorbidities.160 These include urogenital, 
musculoskeletal, psychological, and not least upper GI symptoms.160 Considered as a 
single entity, IBS may be the most common medical disorder in the world.161 Reported 
prevalence rates vary between 1% and 30-50%, without any obvious geographical 
discrepancies.161 Although figures are not available from all countries and regions of 
the world, global prevalence is estimated at 5-15%.161 In the United States, 12% of 
primary care visits, and 28% of gastroenterology practice are accounted for by 
IBS.162,163  
IBS is not associated with mortality, but is typically a chronic disorder.158,160,162,163 As 
such, it has a significant economic impact for both the individual and the society, in 
terms of costs of medical investigations, medication, work absence and decreased 
productivity.164 IBS was reported to incur expenditures increasing 1 billion USD per 
annum in the United States already in 2004.165 Importantly, the disorder is also 
associated with a pronounced reduction in quality of life.164,166 In one large survey, 
seventy percent of patients reported that they missed at least 10 social activities or 
events during a three month period, due to IBS.166 
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Prominent risk factors for IBS include female gender, young age, and a recent episode 
of gastroenteritis.160-162,167,168 Following a severe enteric infection, the risk of 
developing IBS is six-fold increased, corresponding to an incidence of about 10%.168 
Conversely, 10% of IBS is estimated to be post-infectious.168 The association between 
gastroenteritis and IBS has raised questions about the role of microbial imbalance in 
this poorly understood disorder.        
1.6.1 Pathophysiology 
IBS has traditionally been understood as a collection of symptoms from the intestinal 
tract, without any biological correlate. However, recently, advances in molecular 
analysis have demonstrated different abnormalities in subsets of IBS patients. These 
include intestinal dysbiosis, immune activation and even genetic factors.167,169-172 
Nevertheless, no unifying underlying mechanism has been identified. Diagnostic tests 
to identify subpopulations of IBS patients, which could benefit from targeted 
therapeutic interventions, are also lacking.167 
At present, the most distinctive subgroup is post-infectious IBS. The risk of developing 
IBS after a gastroenteritis episode appears to be partly dependent on the severity and 
causative agent of the infection.167,168 However, it is also related to host 
susceptibility.167,168 The relationship between IBS and enteric infections provides 
compelling evidence for microbial imbalance as a causative or contributing factor, at 
least in some patients. In addition, results from therapeutic trials support a pathogenetic 
role for the microbiota.173-176 Reduced intake of certain bacterial metabolic substrates, 
as well as pre-, pro- and antibiotic treatment have all been associated with symptomatic 
relief in subsets of IBS patients.173-176 
Nevertheless, studies of the faecal microbiota composition of IBS patients have yielded 
inconsistent and even contradictory, results.169 Still, there is some evidence for 
decreased microbial richness in a subgroup of IBS patients.169,177 The Proteobacteria 
phylum appears to be increased, and the Bifidobacterium and Faecalibacterium genera 
decreased, in abundance in IBS.169,177-180 In addition, one study indicated that the 
mycobiome could be of importance for IBS-related visceral hypersensitivity. 181 
Relatively few investigations have addressed alterations of the mucus-associated 
microbiota in IBS.177,179 However, microbes inhabiting this niche would be more likely 
to be able to elicit immune responses, influence the enteric nervous system and cause 
damage to the mucus and epithelial barriers. 
Traditionally, IBS has been understood as a psychosomatic disorder. There does appear 
to be an association with psychiatric comorbidities, which cannot be fully explained by 
referral bias.160,162,167 The term brain-gut axis has long been used to refer to the 
relationship between the emotional state and intestinal symptoms. This connection is 
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likely an experience shared by most humans. Still, in recent years, the understanding of 
the brain-gut axis has broadened and deepened considerably. Its definition includes the 
central and enteric nervous system and their inter-connection through the sympathetic 
and parasympathetic autonomous nervous systems, but the signaling pathways are not 
confined to the neurons.182,183 The hypothalamic-pituitary-adrenal axis, 
enteroendocrine cells and the immune system have also been shown to be important for 
the communication between these two organs.182,183 The current understanding is that 
the pathway should be seen as triangular, since it also involves the gut microbiota as a 
third “multi-organism” organ.167,182,183 
IBS has also been conceptualized as a primary disorder of the immune system. There is 
some evidence of a general increase in mucosal immune cell infiltration in subsets of 
IBS patients, occasionally overlapping with observations in microscopic colitis.170, 
184,185 Studies have indicated normal levels of circulating T and B lymphocytes, but 
increased gut homing.170 Augmented local and systemic levels of various pro-
inflammatory cytokines have also been reported.186,187 However, cytokine profiles are 
divergent and have not been linked to a certain T helper cell response category. 
Furthermore, there may be elevated levels of circulating antibodies against both self 
and non-self antigens, including bacterial flagellin and neuronal components.188,189 As 
for the innate immune response, there is one prime suspect: the mast cell. Several 
studies indicate that numbers of total and activated mucosal mast cells are increased in 
IBS.190,191 Mast cell products, including histamine and proteases, have been shown to 
promote visceral hypersensitivity through the sensitization of afferent neurons.192,193 
Interestingly, the prevalence of IBS seems to be increased in ulcerative colitis (UC) 
patients in remission, as well as in coeliac disease patients on gluten free diet.194, 
195This has prompted the hypothesis that IBS may be the clinical manifestation of 
subtle, chronic inflammation. According to this view, IBS and IBD, i.e., inflammatory 
bowel disease, may be more alike than not, as reflected in their acronyms.  
1.7 ULCERATIVE COLITIS 
UC is a chronic inflammatory disease of the colon and rectum. In contrast to the other 
main form of IBD, Crohn´s disease, the inflammation is limited to the mucosa. 
Characteristically, bouts of active inflammation alternate with periods of disease 
remission. The inflammation is continuous, and usually starts from the rectum and 
distal colon. It may (or may not) progress in a proximal direction to affect the entire 
colon. Typical symptoms are frequent and urgent defecations, and rectal bleeding. 
Loose and voluminous stools signal involvement of the more proximal parts of the 
colon. Severe inflammation may be life-threatening if untreated, as there is a risk of 
colon perforation. Sometimes colectomy (acute or elective) may be necessary. UC is 
Early Stage Inflammation and Cancer as Reflected in the Gastrointestinal Mucus Composition 
22 
frequently associated with extra-intestinal complications affecting the bile ducts, joints, 
skin and eyes.  There is also an increased risk of colon cancer, which is proportional to 
the time since diagnosis, and the extent of colon involvement, but not to the number 
and severity of relapses.196 The life-time risk of colon cancer in ulcerative colitis 
patients is estimated at 3-5%.197,198 
The incidence of UC is dependent on age and geography, but not gender.197,199,200 
Reports on prevalence vary greatly between approximately 8-250 cases per 100 000 
people. 197,199,200  There are two age-peaks in its incidence, where the first, and highest, 
occurs in early adulthood.200 There is another more modest incidence increase around 
50-70 years of age.200 UC is most common in North America and Europe.197,199 
However, reports indicate that the incidence of the disease is rising in other parts of the 
world.199 Studies have also shown that migrants to Europe and the US have a higher 
risk of UC than the population from which they originate.201 Taken together, this 
suggests that diet and life-style factors may be of importance for the development of 
the disease. 
1.7.1 Pathophysiology 
Despite decades of research, the aetiology and pathogenesis of ulcerative colitis remain 
insufficiently understood. This indicates that the underlying mechanisms are 
multifactorial, and probably vary between individuals. The current paradigm is that UC 
is caused by inappropriate host-microbial interaction in the large intestine.197, 202 This 
phenomenon likely results from multiple risk factors, both on the host and the 
microbial side, which reinforce each other in a complicated, synergistic interplay.  
Having a first degree relative with UC is associated with a life-time risk of developing 
the disease of about 2%.203 Genome-wide association studies have identified numerous 
loci associated with ulcerative colitis, some of which are shared with Crohn´s 
disease.197,204 However, the concordance in monozygotic twins is less than 20%.205 This 
indicates that genetic factors explain only part of UC pathogenesis.  Moreover, it is 
estimated that established risk loci account for only a fraction of the genetic component 
in UC.204,206,207  
Nevertheless, functional categorization of the genes that have been associated with UC 
in unbiased, genome-wide analyses could shed light on the pathogenetic mechanisms. 
Genes that are likely to have a causative association with UC are linked to innate 
immunity (e.g. CARD9), ER stress (e.g. XBP1, ORMDL1) epithelial barrier integrity 
(e.g. CADH1, HNF4A), suppression of inflammation (e.g. IL10 and its receptor, as well 
as IL1R2), and adaptive immunity.208-213 In the latter category, variants associated with 
the Th17 pathway (e.g. JAK2, STAT3 and IL23R) are particularly 
noteworthy.208,209,212,214 However, interpretation of genome-wide association (GWA) 
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data is difficult. Most variants are not coding (i.e., do not directly influence the amino 
acid sequence of a protein), but regulatory. Only for some of these, a direct link with 
gene expression has been demonstrated. These are known as expression quantitative 
trait loci (eQTL). 
Studies in genetically modified animals can provide biological support for genetic 
variants, and suggest mechanistic explanations. There is a plethora of mouse models 
for colitis. One early example is the Il10-/- model.215 However, genetic models for 
spontaneous colitis are typically protected from inflammation in germ-free conditions, 
or during antibiotic treatment.216 This provides compelling evidence for a role for the 
gut microbiota. Furthermore, although antibiotics have not shown effects in UC, there 
are several studies suggesting a therapeutic potential for probiotics.217,218 UC has been 
associated with a decrease in microbial diversity, particularly affecting the Firmicutes 
phylum.219,220 Species reduced in abundance in colitis include butyrate-producers, such 
as Faecalibacterium Prausnitzii.221 This observation can be understood in the context 
of the well-known anti-inflammatory effects of butyrate, including the induction of 
regulatory T-cells.222,223  
Crohn´s disease is linked to a Th1-dominated adaptive immune response, the key 
effectors of which are macrophages, IgG-producing B-cells and cytotoxic T-cells. By 
contrast, UC has traditionally been associated with a Th2 response, which is linked to 
the activation of eosinophils, basophils and mast cells, through effector cytokines 
including IL4, IL5 and IL13.224 Whereas the Th1 response is also triggered by 
intracellular pathogens, the Th2 profile is induced by extracellular pathogens, including 
helminths, as well as in allergic reactions. However, UC is also associated with a Th17 
response.225 This is likely to be important for the recruitment of neutrophils, which is a 
hallmark of the disease. 
The intestinal mucus is at the interface between the microbiota and the host. Thus it is 
hardly surprising that UC has also been associated with abnormalities of the mucus 
system. Patients sometimes report visible mucus in their stools, although this is not 
pathognomonic for UC. So-called goblet cell depletion is a well-known 
histopathological feature of the disease, although this observation likely reflects 
emptying of goblet cells, rather than an actual reduction in their numbers. Previous 
studies have demonstrated a more permeable mucus layer in UC patients with ongoing 
active inflammation.226 Moreover, mucolytic bacteria such as Ruminococcus torques 
and gnavus may be more abundant in UC.227 
The high production rate and intricate folding of MUC2 exert great demands on the ER 
of the goblet cell. Mutations in genes involved in ER stress response, have been linked 
to UC.210 Interestingly, MUC2 mutations, causing its retention in ER, also induced 
colitis in mice, with evidence of ER stress.228 The potential causal relationship between 
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ER stress and mucus layer abnormalities in UC is unclear, and could well be 
bidirectional.  
The study of mucus has been impeded by its transparency and high degree of 
hydration, which make it difficult to visualize and preserve. Therefore, the protein 
composition of the colonic mucus in humans has not previously been determined. 
Several investigations have focused on mucus-associated microbiota in the gut.131,132 
However, there have been few systematic efforts to stratify the microbiota according to 
their specific niches and compartments. The microbiota of the inner mucus layer and 
crypts is likely to be very restricted, both in diversity and abundance. Nevertheless, 
these select few are in a position to be very powerful regulators of intestinal 
homeostasis, and immune responses. 
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2 SPECIFIC AIMS 
1. Develop a clinically feasible proteomic cyst fluid analysis that can 
identify malignant potential and malignant progression in pancreatic 
cystic lesions. 
2. Define and describe the protein composition of the human colonic 
mucus. 
3. Characterize alterations of the colon mucus proteome in ulcerative 
colitis patients with and without active inflammation. 
4. Identify potential associations between mucus protein composition 
and patient outcome in ulcerative colitis. 
5. Investigate differences in the metaproteomic composition of the 
colonic mucus between IBS patients and healthy individuals 
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3 METHODOLOGICAL CONSIDERATIONS 
An overview of proteomics and mass spectrometry is provided in the Introduction 
section, and detailed descriptions of the methods used in each study are included in 
Papers I-V.  Hence, this discussion will be limited to selected methodological aspects 
that merit further consideration. 
3.1 RECRUITMENT OF STUDY PARTICIPANTS 
For the studies reported in papers I-IV, all participants were recruited among 
individuals referred for endoscopy for clinical reasons (Papers I-II: EUS; Papers III-IV: 
colonoscopy). The IBS patients in paper V were informed about the study during 
scheduled visits to a gastroenterology outpatient unit. The recruitment of the patient 
populations we were investigating was largely uncomplicated. By contrast, the 
selection of appropriate controls generally necessitates careful consideration. 
For a study of pancreatic cyst fluid biomarkers, “healthy” controls are neither feasible, 
nor desirable. In contrast to renal and hepatic cysts, pancreatic cystic lesions are almost 
always a manifestation of an underlying inflammatory or neoplastic disease, although 
patients are usually asymptomatic.31,37,38,47 Thus, inflammatory pseudocysts and cystic 
tumours without malignant potential (serous cystic neoplasms) served as a “control” 
population. Cystic lesions without malignant potential could be identified through 1) 
radiological confirmation of their resolution during an observation period, 2) clinical 
evaluation based on investigation according to consensus guidelines, discussion at a 
multidisciplinary board, and repeat imaging as necessary. In addition, surgery was 
performed for constitutively benign lesions in several instances. This highlights the 
inexact assessment provided by current diagnostic tools, which, moreover, have not 
improved since these studies were initiated ten years ago 
In papers III and IV, controls were selected from patients that underwent colonoscopy, 
but where macro- and microscopic evaluation did not indicate colonic disease. Patients 
with known IBD, other than UC, were excluded. The main cause of referral for the 
control population was iron deficiency anaemia with/without occult or visible blood in 
the stool. Some of these patients did have minor polyps, but with at most low-grade 
dysplasia. Another, perhaps more problematic, category was “controls” with diarrhoea 
and/or altered bowel habits in general. While microscopic colitis was excluded through 
step-wise, random biopsies in patients with diarrhoeal symptoms, we did not attempt to 
rule out IBS. Thus, the prevalence of IBS may have been higher in participants of the 
control group, than in the general population. Nevertheless, studies indicate that IBS 
may also be more common in patients with inflammatory bowel disease, although 
reports are somewhat contradictory.195 Thus, the controls and UC patients may in fact 
Early Stage Inflammation and Cancer as Reflected in the Gastrointestinal Mucus Composition 
28 
have been well matched in this respect. Furthermore, the control patients tended to be 
older than the UC patients with active disease. This likely reflects the fact that altered 
bowel habits after age 50 is considered a “red flag” symptom, due to the age-dependent 
increase in the incidence of colon cancer. We did not observe any age-related 
alterations of the core mucus proteins. Nevertheless, the age difference between 
patients and controls cannot be dismissed as irrelevant, since both the incidence and 
activity of UC appear to abate with advancing age.229-231 Future, larger studies should 
investigate if there are demographic variations in mucus composition and properties.   
In study V, the control population did indeed consist of healthy individuals, as far as 
can be known. These were recruited through an advertisement and screened by 
questionnaires, as well as an interview, to exclude major gastrointestinal complaints. 
The age and gender distribution between cases and controls did not differ significantly. 
3.2 MASS SPECTROMETRY 
3.2.1 Sample collection and storage 
For the proteomic studies of pancreatic cyst fluid biomarkers (Papers I and II), cyst 
fluid obtained at EUS-guided fine-needle aspiration, was directly frozen and stored at -
80⁰C until analysis. Total aspirate volumes varied from a few µl to several ml, 
depending on cyst size. Very small volumes, down to 0.5-5 µl – i.e., a hundred to a 
thousand times less than required for CEA quantification – were sufficient for mass 
spectrometry analysis. Thus, diagnostic yield was not a limiting factor for the method, 
in contrast to standard analyses 
However, sample contamination could pose more of a problem. Blood contamination is 
inherent to the sampling procedure, and could be more pronounced in serous cystic 
neoplasms as well as malignant tumours, which tend to be highly vascularized.47 High-
abundant blood proteins such as albumin and haemoglobin can obscure the proteins of 
interest in the analysis as these are typically present in much lower concentrations. This 
problem is partly circumvented by the use of targeted analysis methods. Nevertheless, 
in Paper II, six samples (corresponding to 4% of patients who fulfilled participation 
criteria) had to be excluded since they were grossly haemorrhagic. 
A more concerning problem, would be contamination by mucus itself. EUS-guided 
aspiration of cyst fluid is performed either via the gastric or duodenal route, depending 
on the location of the lesion. The epithelium of both these organs is coated by secreted 
mucins: MUC5AC and MUC6 in the stomach, MUC2 in the duodenum.23,24,80,232 
However, in these studies, MUC5AC in conjunction with MUC2 produced the best 
peptide biomarker panel for malignant potential. Thus, the procedure-related 
introduction of these mucins into the sample could potentially result in false positive 
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results. The quantitative analysis in Paper II was partly designed to mitigate this 
concern. Our results indicate that contamination of extra-pancreatic mucins did not 
result in concentrations near the threshold levels for our biomarkers. However, these 
studies were performed at a single centre, and, overwhelmingly, by a single 
endosonographist. Thus, multicentre studies will be required to evaluate whether our 
results can be replicated at different settings. 
The collection of colon mucus samples for proteomics was less straightforward, since 
there are no established ways to sample intestinal mucus in vivo. Sigmoid biopsies 
were obtained at routine colonoscopy. However, outside the body the mucus 
immediately collapses due to dehydration. Its transparency also makes it hard to see. 
Hence, it cannot be studied directly. After transport to the laboratory in an oxygenated 
Krebs solution with physiological pH, biopsies were mounted in a horizontal Ussing-
type chamber.233 Solutions containing nutrients and oxygen were supplied from both 
the serosal and apical side of the biopsy, and temperature kept at 37⁰C. Through the 
addition of charcoal to the top of the biopsy, the mucus could be visualized. Typically, 
a thin layer can be observed directly after mounting, likely representing the adherent 
inner mucus. The outer mucus layer is loose, can easily be pipetted away, and thus 
should be lost during sampling and transport.233 The biopsies were left to secrete for 
one hour. Mucus was then collected by gentle scraping and stored together with 
protease inhibitors at -80⁰C. 
One important aspect for the sampling of colonic mucus, which differed between 
Papers III/IV and V, is bowel preparation by laxatives. In Paper V, bowel preparation 
was not performed. When viewed by light microscopy, the mucus appeared less 
transparent and may have retained more shed cells, which could be a disadvantage for 
proteomic analysis. On the other hand, bacterial proteins were not identified in any of 
the 111 samples in Papers III and IV, but were detected in 28% of mucus samples in 
Paper V. This indicates that the metaproteomic composition of colonic mucus samples 
is best studied without prior laxation. 
3.2.2 Sample preparation 
For the studies included in this thesis, MS analyses of two different biological fluids, 
pancreatic cyst fluid and colonic mucus, have been performed. For optimal results, the 
protocols for the preparation must be adapted to the nature of the sample. For instance, 
mucus is more efficiently solubilized by guanidine hydrochloride than by the more 
common denaturant, urea.234 In studies III-V, steps had to be added to ensure the 
removal of the charcoal particles used to visualize the mucus in the ex vivo chamber.233  
Sampling of an exact volume of mucus can be difficult, given its viscous nature. 
Nevertheless, this could be achieved for the cyst fluid samples. By contrast, for the 
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targeted quantification of MUC2 in mucus from colonic biopsies, a different approach 
had to be adopted. The ex vivo chamber enables sampling of mucus from a fixed tissue 
area. However, mucus thickness varies between individuals and samples. Thus, we 
measured the thickness of the mucus as previously described; using this value to 
calculate the sample volume.233 Subsequently, the mucus concentration of MUC2 
molecules for each patient could be calculated. For the relative quantification studies, 
the intensity for each peptide/protein was normalised to the summed intensities of all 
peptides/proteins in that sample. Thus, the normalised intensity values used to compare 
protein abundances between patients represent proportions of total intensity. This 
approach largely neutralizes the effect of sample volume on protein quantification.    
For the proteomic profiling of cyst fluid mucins (Paper I) traditional SDS-PAGE one-
dimensional gel electrophoresis was performed, to separate the cyst fluid proteins by 
mass. The high mass area corresponding to the known molecular weights of the mucins 
was then cut out and prepared for mass spectrometry. As this project was extended to 
develop the method into a targeted, quantitative test (Paper II), the gel-based approach 
was replaced by filter-aided sample preparation (FASP).235 This method has numerous 
advantages over in-gel digestion: it provides access to the full (more or less) mass 
range of the proteome, is more reproducible, and has a shorter work-flow. Thus, it is 
more compatible with high throughput, and potential clinical use. Furthermore, it also 
allows for downstream absolute protein quantification. Hence, the FASP technique was 
used for the other studies in this thesis (Papers II to V). 
 
3.2.3 Targeted protein quantification by Parallel Reaction 
Monitoring (Papers II-III) 
Traditional discovery phase proteomics provides a broad overview of the proteome of a 
biofluid or tissue during physiological or pathological conditions, and is therefore ideal 
for the identification of biomarker candidates. However, the broadness of the approach 
also results in a lower sensitivity and reproducibility. Furthermore, it is not inherently 
quantitative. The relative abundance of a protein in a sample can be estimated through 
the intensity values of its peptide ions in the MS analysis. The intensity for a peptide 
corresponds to how often its particular mass-dependent oscillation frequency signal is 
registered by a detector. Still, this does not provide information as to the actual 
concentration of the biomarker in a sample. Absolute quantification can be achieved 
through targeted MS analysis, using internal standards to determine the exact 
concentration of a biomarker in a sample. In targeted MS, the analysis is limited to a 
panel of proteins of interest, often putative biomarkers. Prior to the targeted 
experiment, a selection list of proteins (based on research interest) and peptides (based 
on theoretical properties or observations from explorative studies) is constructed. 
Before analysis, a retention time window and a mass/charge selection filter, 
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corresponding to the chosen peptide/s is applied. Thereby, the analysis is restricted to 
the peptides of interest, greatly enhancing the sensitivity for their detection.8,9 Modern 
mass spectrometers allow for the selection of multiple, narrow mass windows, such 
that several peptides can be analysed in one run. In Paper II we employed a technique 
known as Parallel Reaction Monitoring (PRM).10 There, after the selection of a 
precursor peptide, fragmentation is performed, followed by quantification of all the 
product ions (fragments). The analysis was performed on a Q Exactive instrument, 
which is a hybrid of two units: a quadrupole, which can be used as a mass filter, and an 
Orbitrap mass analyser.236 Simply put, the quadrupole consists of four parallel metal 
“rods” which creates a very narrow trajectory for the ions. This allows for a precise, 
mass/charge-based selection of peptides for analysis. Following fragmentation in the 
collision cell, the product ions are analysed in the Orbitrap unit. 
 
The internal standards used in MS-based absolute quantification typically represent 
synthetic, custom-ordered stable-isotope labelled variants of the peptides of interest. 
This means that the synthetic peptides will have almost the same m/z-values as their 
“native” counterparts, but can be distinguished from these through a slight mass shift. 
Since the concentrations of the heavy peptides are known, the corresponding 
concentrations of the (light) peptides of interest in the original biological sample can be 
deduced.  
 
The proper selection of peptides to quantify is essential for the success of the 
experiment, but can be quite challenging. The inclusion of amino acids that are 
frequently modified (for instance methionine, which contains a sulphur group that can 
be oxidized), chemically unstable sequences and missed cleavage sites, means that 
results may not be reproducible and reliable. Mucins contain long, repetitive sequences 
that are heavily glycosylated, and not possible to detect in the MS analysis.23,24 
Nevertheless, since they are very large proteins, they still offered a good choice of 
possible biomarker peptides.   
3.3 HISTOLOGY AND IMMUNOHISTOCHEMISTRY (PAPERS IV-V) 
In Papers IV and V, the proteomic investigation was complemented by a number of 
histological and immunohistochemical analyses. Carbol fuchsin and malachite green 
were used to visualize endospores which cannot be readily observed by common 
bacterial staining methods. In malachite green staining, heat is used to “force” the dye 
into the thick spore wall, where it is retained. The Brachyspira “fringe” characteristic 
of intestinal spirochetosis, was easily detectable by an Alcian blue/Periodic acid-Schiff 
(PAS) stain, as illustrated on the cover of this thesis. Hematoxylin-eosin (H&E) stained 
slides were used for the quantification of immune cells (except mast cells) which were 
counted in five high power fields (magnification x 600). Mast cells were counted in 
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toluidine blue stained sections, where they are stained pink-purple by the 
metachromatic dye. Toluidine blue was also useful for the visualization of bacteria 
inside crypts, probably due to its staining of acidic components, including nucleic 
acids. Gram stain, in conjunction with immunohistochemical staining for lipoteichoic 
acid, was used to visualize the presence of other bacteria inside crypts in patients with 
intestinal spirochetosis. Lipoteichoic acid is a component of Gram positive bacteria, 
whereas Brachyspira are Gram negative. 
3.4 STATISTICS 
Given the complicated sampling techniques, and the relatively advanced and costly 
analysis methods used, the study populations were not very large for any of the studies 
in this thesis. However, the total number of participants exceeded one hundred in 
Papers II-IV. Still, distinct discovery and validation cohorts, as well as stratification of 
patients based on their clinical characteristics (symptoms, disease activity, histology 
findings, prognosis, etc.) meant that many comparisons involved smaller groups. 
Therefore, non-parametric analyses (Fisher Exact test, Mann-Whitney U-test or 
Kruskal Wallis test, depending on the nature of data and the number of groups) were 
generally used. The Bonferroni or Holm-Bonferroni methods were applied to adjust the 
threshold of significance in the event of multiple comparisons. 
 
The novel methods or sample types also meant that power analyses could not be 
performed prior to the investigation. In Papers I, II and V, results from a discovery 
cohort could be used to estimate the required sample size for a validation cohort. Paper 
III should be regarded as an explorative study, and Paper IV as a pilot study. 
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4 RESULTS 
4.1 PROTEOMIC IDENTIFICATION OF CYSTIC PANCREATIC CANCER 
PRECURSORS -- PAPERS I AND II 
4.1.1 Main observations 
• Mass spectrometric quantification of mucins MUC5AC and MUC2 
in pancreatic cyst fluid identified cystic cancer precursors with 97% 
accuracy. 
• The accuracy for the detection of cancer/high-grade dysplasia in a 
cystic lesion was 94%, based on a panel of peptides from proteins 
MUC5AC and PSCA. 
• The performance of the analysis represented a significant 
improvement upon state-of-the-art diagnostic tools. 
• The method is compatible with high-throughput analysis of clinical 
samples and offers several advantages, including very low sample 
requirements and simultaneous quantification of multiple 
biomarkers. Thus, the approach described in Paper II could facilitate 
the development and analysis of biomarker panels for other 
neoplastic/non-neoplastic conditions.  
4.1.2 Rationale 
Reported prevalence rates of pancreatic cystic lesions have surged in the last decades, 
due to advances in imaging quality, as well as in awareness of the underlying 
conditions.31,32,34,35 A significant proportion of this increase is thought to be accounted 
for by mucinous neoplasms – MCN and IPMN –  which are forerunners of pancreatic 
cancer.31,36 Unfortunately, the lack of robust diagnostic tools hampers the identification 
of high-risk cystic lesions.31,37,38,59-66 Hence, the improved detection of macroscopic 
precursors has not yet translated into a reduction in pancreatic cancer mortality. 
Aberrant expression of secreted mucins is a well-known feature of MCN and IPMN, 
which also explains their cystic nature.47,48 Moreover, their mucin profiles have been 
suggested to correlate with prognosis.50,51 Previous studies on mucin expression in 
pancreatic tumours overwhelmingly used antibody-based approaches.47,48,237 However, 
due to the extensive and variable glycosylation of mucin proteins this method is not 
ideal for their detection.23,24 In particular, cancer-related alterations of the glycans 
could result in failure of the antibody to recognize its epitope.23 Thus, we wanted to 
exploit our access to front-end expertise in interventional EUS, mucin biology and MS-
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based proteomics, to identify clinically feasible cyst fluid biomarkers for pancreatic 
cancer precursors. 
4.1.3 Proteomic mucin profiling of pancreatic cystic 
lesions 
In contrast to other mucins, MUC6 is known to be expressed by normal pancreatic 
epithelium (ductal and acinar), as well as by the intrinsically benign serous cystic 
neoplasms.232,238 Therefore, we hypothesized that detection of any mucin except MUC6 
in cyst fluid, should be indicative of an, at best, premalignant lesion. Given the known 
role of MUC1 in both pancreatic and extra-pancreatic malignancies, we additionally 
conjectured that cyst fluid MUC1 content is indicative of malignancy/high-grade 
dysplasia (HGD).23,24  
Briefly, cyst fluid aspirates were prospectively obtained from 78 (discovery cohort: 28, 
validation cohort: 50) patients referred for endoscopic ultrasound (EUS)-guided fine-
needle aspiration of pancreatic cystic lesions. Following SDS-PAGE gel 
electrophoresis, high mass areas (corresponding to the molecular weight of mucins) 
were excised, and analysed by nano-LC MS/MS. The mucins detected in cystic 
tumours were, in order of the frequency of their identification: MUC5AC, MUC1, 
MUC6, MUC5B, MUC2 and MUC16. MUC5AC was detected in 31/37 (84%) of 
cystic lesions with malignant potential, MUC1 in 23 lesions (62%) and MUC2 in only 
9 lesions (24%). However, certain pre-/malignant tumors were uniquely identified by 
MUC2. 
According to histology or clinical follow-up, 37 out of 79 (47%) lesions analysed had 
malignant potential. Proteomic mucin profiling identified these tumours with 97% 
accuracy, which compared favourably to cytology (71%), and cyst fluid CEA (78%; 
p<0.001 for both comparisons). Moreover, cyst fluid MUC1 content correctly 
classified 26/29 lesions with available histology, with regard to the presence or absence 
of cancer/HGD. Thus, mucin profiling demonstrated an overall accuracy of 90% for 
the detection of malignant progression, as compared to 52%, 57% and 59% for 
cytology, cyst fluid CEA, and EUS morphology, respectively. In particular, mucin 
profiling detected 14/16 malignant lesions, corresponding to a sensitivity of 87%. By 
contrast, a combination of traditional methods achieved a sensitivity of merely 50%. 
There were no substantial differences in the performance of the proteomic analysis 
between the cohorts; in fact, the accuracy was higher in the validation set, both with 
regard to the detection of malignant potential and cancer/HGD. 
In conclusion, the proteomic mucin profiling method demonstrated accuracy results 
significantly superior to traditional state-of-the-art analyses, for the identification of 
cystic pancreatic cancers and precursor lesions.  But did the method fulfil our objective 
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of clinical feasibility? At that time, with a relatively modest number of referrals of 
pancreatic cystic lesions for EUS, and within our institution, the answer would 
probably be affirmative. However, the subjective and non-quantitative elements of the 
method were a concern for the reproducibility of the analysis. These included the 
cutting of gel bands and the data-dependent shot-gun mass spectrometry analysis, 
where proteins low in concentration may not be selected for fragmentation and analysis 
if obscured by abundant ones, such as blood components. Moreover, cross-
contamination of mucins from the stomach or duodenum during sampling, could 
potentially compromise the specificity of the analysis.23,24,80,232 With increasingly 
sensitive mass spectrometers, we anticipated that these contaminants may sooner or 
later end up on the “wrong” side of the detection threshold. We reasoned that these 
problems could best be mitigated through the development of a targeted, quantitative 
analysis.  
4.1.4 Identification of cyst fluid biomarker candidates 
through an explorative analysis 
For initial explorative evaluation, aspirates from 24 well-characterized lesions were 
selected. These included six inflammatory pseudocysts and three samples from of each 
of the most common forms of cystic tumours, including IPMN histological subtypes. In 
total, there were nine benign, five premalignant and ten malignant lesions. With the 
exception of one highly typical serous cystic neoplasm, detailed histological 
assessment was available for all tumours in the study.  
Briefly, cyst fluid samples were prepared using a modified version of the FASP (filter 
aided sample preparation) method, and analysed by nano-LC MS/MS.235 The 
explorative analysis identified a total of 1385 unique proteins in pancreatic cyst fluid 
(unpublished data). When single occurrences were excluded, 541 proteins were found 
to be unique to lesions with malignant potential while 273 proteins were exclusively 
observed in malignant lesions. Thus, there were major differences between patient 
categories already in terms of protein identifications, creating a large pool of putative 
biomarkers. 
As discussed in the Methodology section, in mass spectrometry it is usually not 
proteins, but peptides that are analysed. Therefore, in the selection of markers for 
targeted quantification, not only the performance of the protein biomarker in the 
explorative analysis was considered. The choice of peptides that could be stably and 
reproducibly detected in the patient samples also influenced biomarker selection. In 
addition, only secreted or plasma membrane proteins were considered to be 
biologically relevant biomarkers. Filtering according to these criteria resulted in a final 
list of 30 peptides from eight biomarker proteins. These included the proteins MUC1, 
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MUC2, MUC5AC, CLCA1, FCGBP, DMBT1, MSLN and PSCA.82 Between one and 
ten peptides from each marker were selected for quantification.  
The epithelial/histological sub-type of an IPMN has been shown to be an important 
predictor of clinical outcome. Pancreatobiliary-type IPMN have the lowest survival 
rates, while gastric-type IPMN are generally indolent, and intestinal-type IPMN have 
an intermediate prognosis.50,51 Therefore, in addition to biomarker candidates for 
malignant potential and cancer/HGD, putative markers for intestinal-type IPMN 
(MUC2), and pancreatobiliary-type IPMN (PSCA) were also included.  
4.1.5 Detection and assessment of cystic precursors of 
pancreatic cancer by targeted mass spectrometry 
Targeted mass spectrometry analysis by Parallel Reaction Monitoring was used to 
quantify biomarker candidates identified in the explorative phase.10 As for the previous 
study, pancreatic cyst fluid samples were obtained by EUS-guided fine-needle 
aspiration. In a training cohort of 80 individuals, biomarkers were tested, receiver-
operating characteristic (ROC) curves generated, and optimal cut-offs determined, 
using the Youden index. The biomarkers were then evaluated in a validation set of 68 
pancreatic cystic lesions. Prevalence rates of malignant potential and HGD/cancer in 
the cohorts were, respectively, 45% and 19% in the training set, and 71% and 20% in 
the validation set, based on our endpoints. Briefly, in addition to surgery, results of 
clinical follow-up were accepted as a diagnostic standard. To exclude HGD/cancer, an 
observation period of at least three years was mandated, unless the lesion was 
obviously benign (for instance resolved spontaneously during follow-up). 
Based on results from the training cohort as well as previous knowledge of the biology 
of pancreatic cystic tumours, the best biomarkers for malignant potential were found to 
be MUC5AC and MUC2. Cyst fluid levels of these proteins were determined based on 
quantification of a combined panel of 15 peptides. In the validation cohort, this panel 
could distinguish pre-/malignant tumours from intrinsically benign, with an accuracy 
of 97%. Corresponding results for CEA and cytology were, respectively, 61% and 
84%. Full performance characteristics of targeted MS and standard cyst fluid analyses 
for the identification of cystic lesions with malignant potential in the validation cohort 
are shown in Figure 8A.  
For the detection of HGD/malignancy, the best-performing panel was MUC5AC and 
PSCA, with an accuracy of 94% in the validation set. In particular, the sensitivity of 
the analysis at 95% (whole study population) compared favourably to results for CEA 
and cytology, which were 54% and 56%, respectively (p=0.008 and p=0.007). 
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Current clinical guidelines are based on three parameters: cyst size, morphology and 
pancreas-related symptoms.37,38,43 The size of the cyst, as well as whether it was 
suspicious for malignancy, was prospectively recorded in the EUS examination. 
Patients filled out a questionnaire about their symptoms before, or soon after, EUS. In 
Figure 8A. Performance characteristics of targeted MS analysis of peptides from MUC5AC 
and MUC2, and MUC5AC alone, for the detection of pre-/malignant pancreatic cystic lesions. 
Results for standard methods (cyst fluid CEA and cytology) are also provided. 
Figure 8B. Full diagnostic outcomes for the different cyst fluid analyses for the detection of 
pancreatic cystic lesions with malignant potential. Originally published by the American 
Society of Clinical Oncology. Jabbar KS, et al: JCO 2018; 36(4):367–375. 
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our study population, the sensitivity and specificity results of cyst size (cutoff ≥ 3 cm), 
EUS morphology and pancreas-related symptoms for HGD/malignancy were, 
respectively, 55 and 39%, 50 and 94%, and 85 and 31%.  
As predicted, MUC2 levels were elevated in intestinal-type IPMN, as compared to 
other sub-types (p=0.002). PSCA concentrations were significantly higher in 
pancreato-biliary type IPMN (p=0.007). Thus, these two biomarkers could potentially 
identify the vast majority of high-risk IPMN and – given the predominance of this 
tumour type— high-risk cystic neoplasms in general.50,51 However, due to the 
relatively small number of resected IPMN (n=21) in this study, these results will 
require further validation. 
Low cyst fluid and cellular yield, respectively, can be a limitation for biomarker 
quantification and cytological assessments.64 Thus, in a separate analysis, all results for 
each method in Paper II (including inconclusive and missing data) were taken into 
account in an “intention to diagnose” approach. This analysis was restricted to lesions 
where aspiration was successful. Grossly haemorrhagic samples, not considered to be 
representative of cyst fluid, were excluded. Figure 8B shows the full diagnostic 
outcomes for targeted MS and standard methods, for the detection of pre-/malignant 
lesions in the validation cohort. With this mode of analysis, targeted MS correctly 
classified 66/68 (97%) patients with regard to the malignant potential of the lesion. By 
contrast CEA returned correct results in 30/68 (44%) and cytology in 47/68 (69%) 
patients (p<0.001 for the comparison with targeted MS, in both cases). Furthermore, 
the MS analysis was able to detect 95% of lesions with HGD/cancer in patients where 
EUS-FNA was successful, as compared to 35% for CEA and 50% for cytology 
(p<0.001 and p=0.003). 
4.1.6 Discussion and clinical implications 
Taken together, targeted MS analysis of just three cyst fluid biomarkers could identify 
cystic precursors of pancreatic cancer and detect malignant progression within these 
lesions, with an overall accuracy around 95%. The diagnostic performance of the MS 
analysis was significantly superior to current state-of-the-art analyses. Moreover the 
same biomarker panel showed promise for the prediction of high-risk lesions. 
Apart from the performance of the biomarkers, the main strength of the targeted MS 
analysis is the low cyst fluid requirements, as highlighted in the previous section. In 
both Paper I and Paper II, premalignant cystic tumours tended to be quite small, with a 
median diameter around 2 cm. Consequently, CEA could not be analysed for about 
40% of lesions with malignant potential, in both studies. This is in keeping with results 
from previous reports.64 Similarly, cytological assessments are often hampered by the 
low cellularity of pancreatic cyst fluid.62-65 In both studies, a cytopathology technician 
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was present on-site during sampling, for instant assessment of cellular yield. 
Nevertheless, there were some inconclusive results. By contrast, for the targeted MS 
analysis very small volumes of cyst fluid were utilized, corresponding to one 
hundredth to one thousandth of the volume requirement for CEA quantification. 
Moreover, the selected biomarkers in both studies were either secreted or 
transmembrane (with the potential to be shed) proteins. This means that cellular yield 
is not a limiting factor for the method, which also represents an advantage over 
genomic analyses.  
Thus, diagnostic performance and cyst fluid requirements are factors in favour of the 
clinical feasibility of the method. By contrast, lack of equipment and expertise could 
constitute a bottleneck for its clinical introduction. However, MS-based methods have 
in fact long been used in health care in a small scale, such as for the diagnosis of 
inborn errors of metabolism.239 Unlike explorative MS, the targeted method focuses on 
a limited number of proteins and peptides, which could allow for semi-automated, 
high-throughput analysis.10 Furthermore, targeted MS has general advantages over 
standard, antibody-based methods for diagnostic evaluation, including the ability to 
analyse large panels of biomarkers in parallel.8-10 Therefore, it is reasonable to assume 
that it could become a common diagnostic modality in the future.  
The cost of the MS-based analysis of a patient sample is hard to properly assess at 
present. Importantly, it must also be viewed in the broader context of the current 
situation and options for this patient group. Presently, the decision whether to resect a 
lesion is based on consensus documents.37,38,43 The American (AGA) and international 
(Fukuoka) guidelines have been evaluated by a recent study.37,43,240 By adhering to 
these guidelines, 25% and 19% of cancers were missed respectively.240 By contrast, for 
75% of resected lesions malignant progression could not be verified.240 Surgery may 
still have been appropriate for some of these cases. However, previous reports and our 
own experiences indicate that histology frequently does not match the preoperative 
assessment that resulted in resection. This is concerning, since pancreatic surgery is 
still associated with non-negligible mortality, and considerable, sometimes life-long, 
morbidity.32,38  
Current guidelines recommend regular follow-up of pancreatic cystic lesions where 
malignant potential cannot be excluded, up to every 6 months.37,38,43,241 As reviewed in 
the Introduction, such lesions are common in the general population.31,35,38 The 
psychological effects of this stringent follow-up programme have not been 
comprehensively evaluated. Still, in the age of information-seeking, it must be 
expected to cause considerable anxiety, although the actual risk of malignant 
progression is often low. Importantly, with better diagnostic tools, follow-up could 
likely be reduced or avoided in many individuals.  
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One limitation of the MS-based approach is related to the “field defect” phenomenon. 
This means that IPMN not only have malignant potential, but also imply a broader risk 
of pancreatic cancer developing synchronously or metachronously from distinct macro- 
or microscopic precursors.58 However, cyst fluid analysis can only assess the 
malignancy status of the sampled lesion.  
Finally, an important factor to consider is the changing spectrum of cystic lesions 
referred for EUS analysis.32 This shift is obvious from the differences in the 
distribution of diagnoses between the discovery and validation cohorts in Paper II. The 
most apparent change is the decrease in the proportion of pseudocysts and increase in 
IPMN over time. This upsurge in incidentally detected cancer precursor lesions will 
place great demands on accurate diagnostic tools that allow for detailed and 
individualized risk predictions. 
4.2 COLONIC MUCUS PROTEIN COMPOSITION IN RELATION TO 
ULCERATIVE COLITIS PROGNOSIS AND PATHOGENESIS -- 
PAPERS III AND IV 
4.2.1 Main observations 
• The function of the colonic mucus barrier is maintained by less than 
thirty protein constituents 
• Core structural mucus components are reduced in active ulcerative 
colitis 
• Structural weakening of the mucus barrier occurs independent of 
inflammation, and may be important for the development of the 
disease 
• The ratio of interacting proteins LRRFIP1 and FLII, which 
differentially regulate the sensing of microbes, predicts natural 
history in ulcerative colitis 
4.2.2 The protein composition of the colonic mucus 
barrier 
UC pathogenesis is currently understood as an inappropriate host response to intestinal 
microbiota, against a background of genetic susceptibility.197,202,206 However, colonic 
microbes are normally segregated from the host immune system by a filter-like, 
secreted mucus layer.80,81 Mucus barrier failure has been demonstrated in a high 
proportion of patients with active UC.226 Still, the underlying mechanisms and their 
causal relationship with the inflammation, have not been established. The investigation 
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of the potential role of mucus compositional abnormalities in UC has been impeded by 
a lack of characterization of the baseline state.  
Therefore, in a study of mucus sampled ex vivo from sigmoid colon biopsies from 47 
individuals without colonic disease, we determined the protein constituents of the 
mucus barrier. About half (47%) of these individuals were female, and the age range 
was 23-87 years. As discussed in the Methodology section, these participants were not 
healthy volunteers, but patients that had been referred for colonoscopy due to various 
symptoms. The most common cause of referral was anaemia. However, none of these 
individuals had known inflammatory bowel disease, or observable macro-/ microscopic 
colon pathology. 
To define the protein components of the mucus barrier, the proteomic dataset was 
systematically filtered. Intestinal epithelial cells have a high turnover, and are 
constantly shed into the mucus. Thus, intracellular proteins were ubiquitous in the 
samples. Nevertheless, these proteins are unlikely to have a functional role in the 
mucus. Proteins destined for the secretory pathway (i.e., bound for the membrane, ER, 
Golgi apparatus, or the extracellular space) typically possess a particular signal 
sequence at their N-terminus. This feature was used to select for secreted and 
transmembrane proteins. Subsequently, proteins with an ER retention sequence motif 
were excluded. Predicted plasma proteins, likely deriving from the biopsy sampling, 
were also removed from the list.242 Interestingly, out of a median of 955 protein 
identifications in the mucus samples, after systematic filtering and manual curation 
only 29 were found to potentially constitute “true” mucus components. 
The shortlist of mucus proteins included homologues of known constituents in mice 
such as FCGBP, CLCA1 and ZG16, but also non-goblet cell derived proteins such as 
immunoglobulins.82 Equally interesting, perhaps, are predicted mucus constituents not 
identified by the analysis. One example is trefoil factors, the small size and amino acid 
sequence of which likely hamper the generation of unique tryptic peptides that can be 
identified by MS.243 Classical Paneth cell-derived antimicrobial proteins/peptides were 
also absent from the colonic samples, although abundant in ileal mucus.244,245  
4.2.3 Structural weakening of the colonic mucus barrier 
precedes inflammation in ulcerative colitis 
Having investigated the composition of the colonic mucus barrier under normal 
conditions, we proceeded to determine whether it is affected in UC. To this end, mucus 
was collected from sigmoid colon biopsies from 64 UC patients, and analysed by nano-
LC MS/MS. Based on a synthesis of symptoms, overall endoscopy findings and 
histology, 36 patients were found to have active disease, while 28 patients were in 
remission. Patients were also separately stratified according to the histology of the 
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sampled segment. Using this definition, only 15 mucus samples were representative of 
active inflammation. Samples obtained from 47 individuals without colonic disease in 
the same way and during the same period, as previously described, served as controls. 
The analyses were focused towards the core mucus proteome. 
Label-free, relative quantification of mucus proteins revealed a pronounced reduction 
in MUC2 in UC patients with ongoing disease activity. This was verified through MS-
based absolute quantification in a separate, smaller cohort. Other core components 
including FCGBP, CLCA and ZG16 were also lower in abundance in patients with 
clinically active UC, according to relative quantification. By contrast, no differences 
were observed in UC in remission, except for higher levels of two eosinophil-derived 
proteins. 
Strikingly, when the levels of mucus proteins were compared between active UC 
patients with (n=15) and without (n=18) inflammation of the sampled segment, core 
constituents MUC2 and FCGBP were found to be equally reduced in both groups. This 
phenomenon was observed even in mucus from tissue scored as Sandborn 0; i.e., 
normal histology, with no evidence of immune cell infiltration.246 Thus, structural 
weakening of the mucus barrier occurs independent of, and likely prior to, overt 
inflammation.  
Classical immune cell derived proteins, such as the calprotectin dimer, were only 
elevated in mucus samples from inflamed tissue. By contrast, an increase in the mucus 
levels of pro-inflammatory cytokine IL18 was observed in all samples from patients 
with clinical disease activity, regardless of the inflammation status of the sampled 
segment. Analysis on the peptide level revealed a selective increase of the bioactive 
part of IL18. By contrast, the abundance of the N-terminal fragment, which is cleaved 
off during activation, did not differ from controls. This argues for increased secretion 
of activated IL18, rather than cellular contamination, as the most likely explanation for 
our observations. IL18 is activated through caspase 1-mediated cleavage during 
inflammasome assembly in epithelial or hematopoietic cells, and thereupon secreted to 
exert its pro-inflammatory effects.247 The lack of significant immune cell recruitment 
in the majority of patients with elevated mucus IL18 in this study, suggests that the 
secreted IL18 at least partly derived from the epithelium. Thus, epithelial 
inflammasome activation may be an early event in UC pathogenesis.  
Since the lower levels of core mucus components in active disease could not be 
explained by inflammation and tissue damage, aberrations of mucus secretion were 
evaluated as an alternative mechanism. Goblet cells in the surface epithelium 
constitutively secrete mucus through the merging of single granules with the 
membrane.248 By contrast, upper crypt goblet cells are capable of releasing their entire 
mucus content in a coordinated burst, known as compound exocytosis.249 A specialized 
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goblet cell sub-type, the sentinel goblet cell, has previously been shown to orchestrate 
this response. These cells sense ligands of TLR2, 4 and 5 (including microbial 
components such as LPS), and mount a secretory response mediated by NLRP6 
inflammasome activation.102  
Using apical administration of a synthetic ligand of TLR2, the compound exocytosis 
response was evaluated in ex vivo biopsies from patients with active UC, patients in 
remission and individuals without colonic disease. While stimulation with the ligand 
resulted in increased mucus growth both in controls and UC patients in remission, this 
response was abrogated in active UC. 
As previously discussed, NLRP6 inflammasome activation is involved in the induction 
of sentinel goblet cell dependent mucus secretion.102 Thus, our results suggest that 
epithelial inflammasome assembly, resulting in activation of the upper crypt compound 
exocytosis response, could be an early event during the development of colitis. 
However, frequent or constant stimulation of this mechanism may result in insufficient 
time for mucus production, lower level of structural components and, ultimately, 
weakening of the mucus barrier. 
4.2.4 Compositional alterations of penetrable mucus 
samples 
To further test our explanatory model, we examined the composition of penetrable 
mucus samples. Briefly, mucus penetrability was assessed in parallel with sample 
collection for MS analysis in 49/111 patients (including 25 with active UC, 15 with UC 
in remission, and 9 controls) using fluorescent beads as surrogate markers for 
bacteria.226 Based on this analysis, nine (36%) patients with active UC, three (20%) 
with UC in remission, and one control (11%) were found to have mucus barrier failure. 
As expected, there was a strong tendency towards a reduction of MUC2 in penetrable 
mucus samples. However, neither this difference, nor other alterations of the core 
mucus proteins, was statistically significant. Based on the observation that the goblet 
cell compound exocytosis response to a TLR2 ligand was abrogated in active UC, we 
sought to identify markers for this type of secretion. In contrast to constitutive 
secretion, compound exocytosis involves the release of whole mucus granules, rather 
than just their contents. Thus we identified a group of mucus proteins that 1) are known 
mucus granule components, but lack signal peptides for secretion, indicating that they 
form part of the granule membrane 2) exhibited a correlation with MUC2 levels in the 
MS analysis, and 3) were identified in the majority of mucus samples.250 Among these 
proteins, BCAP31 and RAB10 showed the strongest correlation with MUC2. However, 
interestingly, this correlation was restricted to UC patients. Given that they are likely to 
be granule wall components, BCAP31 and RAB10 should be released only through 
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compound exocytosis, making them potential markers for this secretory mechanism.102, 
249,250 Both BCAP31 and RAB10 were significantly reduced in penetrable mucus 
samples. Taken together, this implies that the goblet cell compound exocytosis 
response to microbial components is abrogated in active UC, likely due to exhaustion. 
Furthermore, this secretion mechanism may be important for the maintenance of an 
impervious mucus barrier.    
This model of the role of the mucus system in the development of UC does not include 
the initial events, leading to inflammasome assembly. However, these are likely to 
involve increased host-bacterial contact. The mucus penetrability observed in a subset 
of UC patients in remission could potentially indicate an inherent weakness of the 
mucus barrier. This patient group, along with some individuals with penetrable mucus 
despite very mild inflammation, was characterized by lower mucus levels of apical 
chloride-bicarbonate exchanger SLC26A3/DRA.251 As discussed in the following, 
SLC26A3 may be important for mucus barrier formation.  
4.2.5 Mucus protein alterations associated with poor 
disease outcome 
Ulcerative colitis is regarded a chronic disease, but affects individuals very 
differently.197,229-231 While some patients will require repeated corticosteroid regimes 
and even colectomy, others will have only one flare in their lifetime. Currently, there 
are no useful predictive biomarkers for disease activity.231 As described in the previous 
sections, mucus from sigmoid colon biopsies was sampled in 64 UC patients, and 
analysed by proteomics. Sixty-one of these patients (95%) could be prospectively 
followed for 3 years, and 54 patients (84%) for 5 years; allowing us to correlate mucus 
protein composition with clinical outcome. High disease activity during the prospective 
observation period was defined as minimum one relapse per year, or requirement for 
additional maintenance therapy (e.g. thiopurines or TNF alpha inhibitors), 
hospitalization or surgery. Eleven (18%) and 14 (26%) patients, respectively, fulfilled 
this criterion based on 3-year and 5-year follow-up.  
The most promising protein biomarker candidates for poor clinical outcome according 
to our evaluation were LRRFIP1 and FLII. Intriguingly, these proteins are direct 
binding partners that have been reported to differentially modulate TLR4-MYD88 
dependent signaling, and thus the innate response to specific microbial ligands.252-256  
A ratio of LRRFIP1/FLII ≤1 was found to be a significant predictor of high disease 
activity during three years, with an odds ratio of 37. The prognostic value of the 
LRRFIP1/FLII ratio was independent of disease activity at baseline. Furthermore, the 
LRRFIP1/FLII ratio predicted the requirement for intensified medication or surgery 
during a five year period, with a sensitivity of 90% and a specificity of 89%.  
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To better understand the underlying mechanisms behind these observations, the 
localization of LRRFIP1 and FLII was evaluated through immunostaining. Both 
proteins were detected in the colonic epithelium. Furthermore, the staining intensity 
inside epithelial cells appeared to correlate with relative quantification levels in mucus. 
Thus, mucus abundances of these proteins were deemed likely to reflect intracellular 
expression and function.    
Altered TLR4-MYD88 signalling can be expected to result in impaired microbial 
sensing.257 Thus, using histology, the presence of bacteria in the epithelium and lamina 
propria was evaluated. In individuals with a low LRRFIP1/FLII ratio and poor clinical 
outcome, bacterial endospores were frequently detected in the lamina propria, as 
confirmed by two independent staining methods.  
4.2.6 Discussion and clinical implications 
In Papers III and IV, the protein composition of the colonic mucus barrier was studied, 
in homeostatic conditions as well as in UC patients with and without active 
inflammation. In total, mucus samples collected ex vivo from sigmoid biopsies from 
over a hundred individuals were analysed. Moreover, the association between mucus 
composition and the natural history of UC was investigated.   
Remarkably, the core proteome of the mucus was found to consist of less than thirty 
secreted and transmembrane proteins. These included homologues of known mucus 
constituents in mice, such as FCGBP, CLCA1 and ZG16, but also non-goblet cell 
derived proteins such as immunoglobulins, eosinophil granule proteins and 
enterendocrine cell product chromogranin A.82 The latter protein has been reported to 
generate several antimicrobial peptides that may be of importance for mucus-
associated innate defences.258,259 However, classical Paneth-cell derived antimicrobial 
compounds were absent from colonic mucus, although abundant in the ileum. There is 
consensus that these proteins fulfill an important function in the loose mucus of the 
small intestine, where they protect us from pathogen colonization and invasion.244,245 
By contrast, the colon is the site of large-scale microbial harvesting of energy, to the 
benefit of the host.103,112,113 Thus, in this context, physical protection of the epithelium 
through a dense mucus barrier may be preferable to the secretion of microbicidal 
substances. 
Given previous reports on mucus abnormalities in UC patients, we next wanted to 
investigate compositional alterations in UC. We were primarily interested in early 
events, with a potential causative role in the development of colitis. Thus, mildly 
affected or normal-appearing segments were preferentially selected for sampling. Core 
mucus structural components MUC2 and FCGBP were found to be reduced in samples 
from patients with clinically active UC. Intriguingly, this reduction was equally 
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pronounced in mucus collected from non-inflamed segments. This indicates that 
structural weakening of the mucus barrier in UC occurs independent of inflammation 
and tissue damage, implying that it could be important for pathogenesis. Samples from 
non-inflamed segments in patients with active colitis may not fully reflect the early 
stages of the disease. Still, they probably constitute the best “human model” available 
for studying the initiating events behind UC inflammation.  
Since the reduction in mucus core structural components observed in active UC did not 
appear to be caused by an overt mucosal immune response, we proceeded to further 
dissect the underlying mechanisms. Screening the proteomic dataset for markers of 
early inflammation, we detected increased levels of the bioactive form of IL18 in 
mucus sampled from non-inflamed segments in active UC patients. Thus, we surmised 
that epithelial inflammasome activation may be an early event in UC pathogenesis. 
NLRP6 inflammasome assembly mediates the sentinel goblet cell dependent secretory 
response to microbes.102 Hence, persistent epithelial inflammasome activation may 
result in repeated stimulation of this secretion mechanism. Ex vivo investigation using 
a synthetic TLR2 ligand to stimulate goblet cell secretion from biopsies, as well as 
proteomic studies of the composition of penetrable mucus samples, indicated that the 
compound exocytosis response to microbes may be exhausted in active UC. Moreover, 
this phenomenon is likely to be important for the increased penetrability of the inner 
mucus layer observed in colitis.     
Mucus penetrability was not limited to UC patients with clinical activity, but also 
observed in a subgroup of patients in remission, in line with a previous report.226 Thus, 
it is conceivable that a minority of UC patients have intrinsic abnormalities of the 
mucus barrier, resulting in increased susceptibility to colitis. In this study, mucus levels 
of chloride-bicarbonate exchanger SLC26A3 were found to be specifically reduced in 
UC patients who had penetrable mucus in spite of no, or very mild, active 
inflammation. The biological rationale of this finding is underpinned by several, 
independent observations. The importance of bicarbonate secretion for proper 
assembly of the MUC2 protective network following its release into the colonic lumen 
is reviewed in the Introduction.91 Moreover, deficiency of Slc26a3 has been linked to 
mucus barrier failure in mice.251 Finally, the SLC26A3 gene is a known risk locus for 
UC, but not Crohn´s disease.260 Our observations provide a possible biological 
explanation for this association.  
UC patients have a highly heterogeneous disease course.197,229-231 Individualized 
predictions of disease activity could potentially forestall severe relapses and emergency 
colectomies, as well as minimize unnecessary use of medication. In Paper IV, the ratio 
of proteins LRRFIP1 and FLII, which antagonistically modulate TLR4-MYD88 
signalling, was found to be highly predictive of frequent relapses and requirement for 
additional medication and surgery.255 Interestingly, a shift in the balance of these 
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proteins correlated with extensive infiltration of bacterial endospores in the lamina 
propria. To the best of our knowledge, this phenomenon has not previously been linked 
to UC. Spore-forming species encompass several pathogens, including Clostridium 
difficile.261 Interestingly, the TLR4-MYD88 signalling pathway has previously been 
shown to be required for a successful innate immune response during C. difficile 
infection.262 However, there is evidence that more than 50% of the colonic microbiota 
possesses the capacity to sporulate.263 Thus, the identities of the spore-forming species 
observed in UC patients with poor clinical outcome in this study, remain to be 
determined.   
General limitations of the analyses include the composition of the control group, which 
consisted of patients referred for colonoscopy due to clinical reasons. A screening 
programme for colorectal cancer has not yet been implemented in Sweden, but will 
potentially facilitate future studies of the healthy human colon. Furthermore, the biopsy 
and mucus sampling techniques may incur variable contamination by blood 
components and intracellular proteins. Still, there were no discernible, systematic 
differences in contamination between patient categories.  
The characterization of the colonic core mucus proteome in homeostatic conditions as 
well as in colitis, provide a platform for further studies. Functional abnormalities of the 
mucus system have previously been described in UC. However, in the present work 
their underlying mechanisms and temporal association with inflammation were 
comprehensively investigated. Although preliminary, the association between severe 
UC and tissue infiltration of bacterial endospores is compatible with biological and 
clinical characteristics of the disease. Intermittent germination of endospores could 
potentially explain the frequent relapses and poor therapeutic response that characterize 
a subset of UC patients. Taken together, our observations may inform the future 
development of treatment options to strengthen mucus protection and minimize host-
bacterial contact – potentially including probiotic compounds.    
4.3 ASSOCIATION BETWEEN THE BRACHYSPIRA GENUS AND IBS -
-  PAPER V 
4.3.1 Main observations 
• Brachyspira colonization was detected in 34% of IBS patients but 
only 4% of healthy individuals. 
• Attachment of Brachyspira to the colonocyte brush border was seen 
in every fifth IBS patient and associated with diarrhoea and 
accelerated transit 
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• IBS patients with Brachyspira had mild mucosal inflammation, 
eosinophilia and mast cell activation 
• Antibiotic treatment resulted in long-term clinical improvement, but 
promoted relocation of the Brachyspira into crypts and goblet cell 
mucus granules.  
4.3.2 Rationale 
Irritable bowel syndrome (IBS) encompasses a wide range of intestinal symptoms, and 
is unlikely to be explained by a single mechanistic model. Thus, research efforts have 
been directed towards identification of subgroups that could be responsive to targeted 
intervention. The increased incidence of IBS after a gastroenteritis episode, as well as 
positive effects of pre-, pro- and antibiotics in certain individuals, suggest microbial 
imbalance as an underlying factor in a subset of patients.168,174-176 However, studies of 
faecal, and mucosal samples, have not demonstrated consistent alterations of the 
microbiota that could be linked to patient characteristics.169 The colonic inner mucus 
layer segregates the vast majority of bacteria from the host.80,81 Nevertheless, studies 
indicate that this compartment is not sterile, but rather inhabited by a very sparse and 
select flora.135 Although low in abundance, the strategic position of these microbes 
would enable them to influence host physiology and immune responses in a unique 
fashion.  
Therefore, we decided to perform a meta-proteomic study of inner mucus layer 
samples from well-characterized IBS patients and healthy individuals. To investigate 
their pathogenic potential, observations were correlated with clinical parameters and 
investigation of mucosal immune responses. 
4.3.3 Metaproteomic analysis of colonic mucus samples 
identified a potential association between 
Brachyspira and IBS 
Twenty-two IBS patients and 14 healthy volunteers underwent sigmoidoscopy with 
biopsy collection. Biopsies were transported in oxygenated Krebs and mounted in a 
perfusion chamber. Subsequently, mucus was “harvested” through aspiration and 
gentle scraping, as described in the Methodology section.233 Importantly, the outer, 
loose, mucus layer is easily dislodged and should be lost during biopsy sampling and 
transport in the buffer. In support of this, a thin mucus layer, corresponding to the 
previously described thickness of the human adherent, inner mucus layer, could be 
observed directly after mounting of the biopsy in the chamber.233  
Mucus samples were analysed by nano-LC MS/MS as described in Paper V. Searches 
were performed against reviewed human and eubacteria sequences of the Uniprot 
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database. At least three protein identifications at the 99% significance level were 
required to validate the presence of a bacterial family/genus in the mucus. 
In explorative MS analysis, proteins present in low concentrations tend to be obscured 
by high-abundant ones; i.e., not selected for fragmentation and identification. 
Moreover, the bacterial content of the inner mucus layer is expected to be very low, as 
previously discussed. Therefore, it is hardly surprising that bacterial peptides were not 
detected in most samples. On the family level, the most frequent identification was 
Pseudomonadaceae, which was over-represented in IBS patients (p=0.06). The second 
most common family was Brachyspiraceae (genus Brachyspira), detected in 3/22 
(14%) IBS patients, but not in any healthy individuals.  
Brachyspiraceae species encompass well-established pathogens of domestic 
animals.138,140 Brachyspira aalborgi and Brachyspira pilosicoli are associated with a 
condition known as intestinal spirochetosis in humans. Therein, the elongated 
Brachyspira attach to the colonic epithelium in a perpendicular manner, creating the 
impression of a prominent brush border upon histological examination.137-141 In this 
study, the characteristic, continuous spirochete “fringe” could be clearly visualized in 
Alcian-blue/PAS-stained sections in the three IBS patients with proteomic Brachyspira 
identifications in mucus. The presence of the spirochetes at the epithelial border was 
further confirmed through immunofluorescent staining with Brachyspira antiserum.264 
Transmission electron micrographs showed a dense colonization of the epithelial 
surface, with Brachyspira attaching to the apical membrane between microvilli. 
However, there were no obvious signs of damage to the epithelial cell, suggesting that 
Brachyspira is well adapted to long-term colonization of its human host.  
4.3.4 Brachyspira colonization of the colonic epithelium 
and inner mucus layer is significantly more common 
in IBS patients 
Having confirmed our initial observations, we wanted to see if we could detect further 
cases among IBS patients or healthy individuals. To enable rapid screening of biopsy 
material as well as species detection, we set up a targeted real time PCR analysis of 
16S rDNA based on melt curve discrimination, as described by Westerman et al.144 
Using this analysis, in conjunction with immunofluorescent staining, the prevalence of 
Brachyspira colonization in IBS patients was found to be as high as 50% (11/22 
patients), as compared to 7% (1/14 individuals) in healthy controls (p=0.01). For the 
validation of our findings, we had access to a separate cohort of prospectively collected 
Methacarn-fixed, paraffin-embedded biopsies from 40 IBS patients and 10 healthy 
controls. In the validation cohort, Brachyspira prevalence rates were 25% in IBS 
patients and 0% in controls. Again, prevalence rates were based on two independent 
methods: PCR analysis of 16S rDNA extracted from paraffin- embedded biopsies, and 
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immunohistochemistry of tissue sections. These diagnostic methods showed good 
agreement, with a Cohen´s kappa of 0.84. In total, Brachyspira was identified in 21/62 
(34%) of IBS patients, and 1/24 (4%) healthy individuals (p=0.005). Spirochetosis was 
most common among patients with IBS with diarrhoea (IBS-D). In this subgroup, 
Brachyspira was detected in 44% of patients, with similar prevalence results between 
the discovery (50%) and validation (40%) cohorts. 
Immuno-histochemical analysis could be performed in 56 IBS patients and 21 controls. 
Classical, membrane-associated spirochetosis, with attachment of the Brachyspira to 
the colonocyte brush border, was observed in 6/19 (32%) IBS patients from the 
discovery cohort and 5/37 (14%) IBS patients from the validation cohort. Thus, 
membrane-associated spirochetosis was detected in a total of 11/56 (20%) IBS patients. 
By contrast, this phenomenon was not observed in any healthy control (p=0.03). In 
individuals where Brachyspira was identified by PCR, but where no involvement of 
the apical border was seen, spirochetes could typically be detected in the mucus. 
Invasion of the inner layer was also frequently observed. Thus, this condition was 
denoted as mucus-associated spirochetosis.  
There are two known Brachyspira species associated with intestinal spirochetosis in 
humans: B. aalborgi and B. pilosicoli. The existence of a third species colonizing 
humans, denoted as   B. hominis, has been suggested.137-140 In this study, using targeted 
real-time PCR with melting curve discrimination, B. aalborgi/hominis was found to be 
involved in 78% of cases with membrane-associated spirochetosis, whereas B. 
pilosicoli was responsible for 89% of mucus-associated spirochetosis. Thus, these 
species appear to be associated with distinctive colonization patterns, although with 
some niche overlap.  
4.3.5 Membrane-associated spirochetosis was linked to a 
distinctive symptom profile and mucosal immune 
response 
The severity of IBS and its individual symptoms (pain, bloating, bowel habit 
dissatisfaction and general life interference) is traditionally assessed using the IBS 
Symptoms Severity Score (IBS-SSS).265 A second module of this score assesses ten 
extracolonic symptoms (including early satiety, flatulence, nausea, heartburn, 
headache, fatigue, back pain, pain of the thighs, muscles and joints, and urinary 
urgency), which are common in IBS patients. IBS patients with and without 
spirochetosis did not differ with regard to the overall score or the individual items of 
the IBS-SSS. However, patients with membrane-associated spirochetosis had 
significantly less extracolonic symptoms.  
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As part of the study, patients kept a structured diary of their bowel habits for 14 days. 
Based on this data, patients with membrane-associated spirochetosis were found to 
have higher average stool frequency (p=0.04) and looser average stool consistency 
(p=0.02) than IBS patients without Brachyspira. Corroborating these observations, 
they also had accelerated oro-anal transit (p=0.02) as compared to IBS patients without 
spirochetosis. By contrast, individuals with mucus-associated spirochetosis did not 
differ from other IBS patients with regard to these parameters. 
Next, we wanted to assess mucosal immune responses in Brachyspira patients. Using 
H&E-stained sections, differential counting of lamina propria and sub-/intraepithelial 
immune cells was performed, as detailed in Paper V. Patients with membrane-
associated spirochetosis had increased lamina propria infiltration of leukocytes, 
(p<0.001), particularly plasma cells (p<0.001), as compared to IBS patients without 
Brachyspira. Corresponding results for individuals with mucus-associated 
spirochetosis were variable, with some having elevated and others paradoxically low 
immune cell counts. Increased numbers of sub-/intraepithelial eosinophils were also 
observed in patients with classical intestinal spirochetosis, as previously described.266  
Mast cells are not readily identifiable on H&E stained sections, but have been 
implicated in IBS pathogenesis, particularly with regard to visceral hypersensitivity.190-
193 Furthermore, clusters of mast cells had been observed in spirochetosis patients in 
this study, using transmission electron microscopy. Therefore, to visualize mast cells, 
biopsy sections were also stained by toluidine blue. Based on histology, numbers of 
both total and activated mast cells were significantly augmented in spirochetosis 
patients. In addition, mast cell products chymase, tryptase and beta-hexosaminidase 
were more frequently detected in mucus from patients with Brachyspira, according to 
MS. The proportion of activated sub-epithelial mast cells strongly correlated with 
rectal sensitivity in IBS patients with spirochetosis, as well as in healthy individuals. 
By contrast, this correlation was absent in IBS patients without spirochetosis. 
The inner mucus layer represents the first line of innate defence against pathogens – 
although obviously not effective against Brachyspira. Using bacteria-sized fluorescent 
beads, the inner mucus layer was found to be abnormally penetrable in both 
membrane- and mucus-associated spirochetosis. Similar findings are observed in active 
UC.226 However, in contrast to UC patients, individuals with spirochetosis actually had 
increased MUC2 levels in the mucus, indicating elevated mucin production and 
secretion. Moreover, invasion of bacteria into crypts and even goblet cells was seen in 
toluidine-blue stained sections. This finding had not been observed in sections stained 
by Brachyspira antiserum, leading us to hypothesize that these bacteria belong to 
different genera. This was confirmed by Gram staining, and immunostaining with an 
antibody against lipoteichoic acid; both of which demonstrated that some of the 
invading bacteria were Gram positive. 
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4.3.6 Metronidazole treatment resulted in long-term 
clinical improvement but also induced a more 
invasive Brachyspira phenotype 
Available evidence suggests that intestinal spirochetosis should be treated if symptoms 
are present.140,145,146,150 Metronidazole is the best studied antibiotic in this context. 
However, mindful of previous studies which described only partial improvement, it 
was decided to perform the treatment protocol as a pilot study.140,145,146,150 Thus, four 
patients with membrane-associated spirochetosis were treated with metronidazole. 
These individuals were followed for over a year after antibiotic therapy, with careful 
assessment with regard to clearance of the infection, as well as the clinical and 
histological response. 
Traditionally, symptoms and treatment responses in IBS are evaluated using the IBS-
SSS questionnaire.265 The full score ranges from 0-500, with higher values indicating 
more severe symptoms. Thus, the four patients who received metronidazole treatment 
handed in IBS-SSS questionnaires, before and at regular intervals up to 15 months after 
treatment. Three out of four individuals reported clinical improvement after treatment. 
By consensus, a reduction of IBS-SSS exceeding 50 points is considered as a 
significant response in IBS treatment studies.265 The three responders fulfilled this 
criterion at the final follow-up visit (with a mean and median reduction of 186 and 171 
points, respectively) whereas in the fourth patients symptoms were neither better nor 
worse than before antibiotic therapy. However, only one patient was potentially 
“cured” of IBS (defined as IBS-SSS <75).265 Thus, as previously described, the effect 
of treatment appeared to be favourable, but partial.140,145,146,150 The most substantial 
improvement was observed for pain and general life interference.  
The patients underwent sigmoidoscopy six weeks after the completion of treatment, to 
confirm eradication of the infection. Histology demonstrated clearance of the 
spirochetes from the apical membrane, which is how treatment success was established 
in most previous studies. Targeted real-time PCR of biopsy material confirmed a 
dramatic decrease in the abundance of Brachyspira. Immunohistochemistry, on the 
other hand, told a quite different story. Although the spirochetes were largely gone 
from the epithelial surface in the responders (and reduced in abundance in the non-
responder), the Brachyspira had relocated into crypts and goblet cell mucus granules. 
4.3.7 Discussion and clinical implications 
In this study, Brachyspira species were shown to be significantly more common in 
colonic biopsies and mucus from IBS patients. Direct attachment of Brachyspira to the 
epithelial surface was confirmed in every fifth IBS patient, and significantly associated 
with diarrhoea and accelerated gastrointestinal transit. A nearly equal number of IBS 
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patients had Brachyspira colonization restricted to mucus, with no evidence of 
epithelial involvement. By contrast, these individuals did not have diarrhoeal 
symptoms. Taken together, this suggests that the spirochetes cause diarrhoea by 
physically occupying much of the colonic surface where fluid reabsorption should have 
taken place, and possibly inducing structural alterations. Accordingly, membrane-
associated Brachyspira was observed in nearly every third IBS patient with diarrhoea 
(IBS-D), but not in any IBS patient with constipation, nor in any healthy individual.  
However, diarrhoea is not in itself sufficient for an IBS diagnosis, the mainstay of 
which is abdominal pain.158 Furthermore, mucus-associated spirochetosis, which was 
not associated with diarrhoeal symptoms, also seemed to be overrepresented among 
IBS patients. This indicates that Brachyspira also contributes to IBS symptomatology 
through other mechanisms. Host responses observed in this study included mild 
mucosal inflammation with increases in eosinophils and mast cells, as well as mucin 
hypersecretion. This is reminiscent of the Th2 type immunity induced by helminthic 
infections and allergic reactions, where the augmented mucus production is mediated 
by effector cytokine IL13.267,268 Thus, our findings tentatively suggest that the immune 
response elicited by Brachyspira might be Th2 dependent. 
In the context of IBS, our observations of mast cell activation in spirochetosis patients 
may have the greatest immediate relevance. Mast cells have been strongly implicated 
in IBS pathogenesis, particularly with regard to pain and visceral hypersensitivity.190-193 
Numbers of mucosal, activated mast cells are increased in the IBS population, 
according to several studies.190-192 Moreover, mast cell compounds, such as histamine 
and tryptase, are capable of sensitizing and exciting submucosal afferent neurons ex 
vivo.192 In this study, visceral sensitivity correlated with mast cell activation in IBS 
patients with spirochetosis, and healthy controls. However, this correlation was absent 
in IBS patients without Brachyspira. Taken together, our observations tentatively 
suggest that the previously observed association between mast cell activation and IBS 
symptoms may at least partly be explained by concurrent intestinal spirochetosis. 
Brachyspira is well adapted to its unique niche. Although anaerobic, its expression of 
the NADH oxidase (nox) gene allows it to tolerate the oxygen diffusion near the 
epithelium.269 Thanks to its periplasmic flagella, Brachyspira is highly motile.138,140,270 
Furthermore, its swimming speed actually increases in viscous surroundings, like the 
colonic mucus.270 Previous investigations also indicate that Brachyspira expresses 
proteases at its outer membrane which potentially assist its passage through the 
mucus.271 In this study, we observed that IBS patients with spirochetosis had abnormal 
penetrability of the mucus barrier. Although the causal relationship is unclear, it is 
probable that Brachyspira affects barrier properties. Apart from direct, protease-
dependent effects on the mucus network, the massive Brachyspira colonization likely 
overwhelms and exhausts sentinel goblet cell mediated secretory responses.102  
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As reviewed in the Introduction, the pathogenic relevance of Brachyspira is debated. 
Koch´s classical postulates for the association between microbes and disease, state that 
it should be possible to introduce a culture of the microorganism into a healthy 
organism, and thereby cause illness. However, B. aalborgi, the species most commonly 
associated with symptoms in humans, is almost impossible to culture.139 Moreover, 
since it is thought to only colonize/infect primates, experimental models are sorely 
lacking.140 Thus, the pathogenic relevance of intestinal spirochetosis has mainly been 
assessed through treatment studies in humans, often limited to few cases.140,145,146,150 
While antibiotic therapy led to improvement in some patients, it did not always 
produce a full recovery. Similarly, among the four spirochetosis patients treated with 
metronidazole in our study, only one was potentially “cured” of IBS, although another 
two showed significant clinical improvement. This is of course a much too small 
population to draw conclusions from. However, while the placebo response can be 
prominent in IBS patients, it is typically temporary, whereas the patients in this study 
experienced a gradual relief in symptoms over many months.  
Histology and PCR-based quantification six weeks after completion of treatment 
indicated successful eradication of the Brachyspira. Immunohistochemistry alone 
revealed persistence of the infection. Although the spirochetes had largely been cleared 
from the membrane in all three responders, there was evidence of relocation of the 
Brachyspira into goblet cells and crypt lumina. Antibiotic concentrations can be 
expected to be considerably lower in the tightly packed mucus inside the goblet cells. 
Thus, the treatment may have selectively induced the expansion of Brachyspira strains 
with a tropism for colonizing this environment. Moreover, Brachyspira were found to 
penetrate into the crypt base, with the potential of direct interaction with the stem cell 
niche. 
Limitations of the analysis include the low number of control subjects, and the fact that 
patients were recruited from a secondary/tertiary care unit, which means that they may 
not be representative of the IBS population at large. Among the strengths, the rigorous 
clinical characterization of the IBS patients – through validated questionnaires, bowel 
habit diaries, testing of rectal sensitivity and oro-anal transit time – should be 
mentioned. Equally importantly, the use of multiple complementary diagnostic 
methods produced novel insights. The initial observations were made using an 
explorative metaproteomic analysis. However, established techniques such as routine 
histology and 16s rDNA sequencing of stool samples failed to detect Brachyspira in 
the same individuals.  
Taken together, our observations indicate that Brachyspira-associated IBS is linked to 
a distinctive symptom profile and mucosal response, and accounts for up to 20-30% of 
all IBS cases in a Swedish population. Thus, targeted antibiotic treatment may 
conceivably have substantial effects on the morbidity burden of this disorder. 
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However, metronidazole therapy paradoxically induced a more invasive Brachyspira 
phenotype, with the capacity of penetrating down into the crypt base. Hence, our 
findings argue against indiscriminate antibiotic therapy of IBS patients, and underline 
the importance of careful follow-up.  
Importantly, our observations represent a novel microbial strategy to survive antibiotic 
treatment that is unlikely to be restricted to the Brachyspira genus. Bacterial 
persistence during antibiotic treatment, e.g. through biofilm formation or colonization 
of macrophages has been previously described.272,273 Our findings highlight an 
alternative mechanism for evasion of antibiotic action. The large intestine acts as a 
reservoir for multiple pathogens and pathobionts.274 These are not only capable of 
causing gastroenteritis but also conditions ranging from recurrent cystitis to life-
threatening nosocomial infections.274,275 Thus our findings could potentially have broad 
implications for the understanding of bacterial persistence and chronic or relapsing 
infectious diseases. 
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5 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
The studies in this thesis not only encompass three different disorders, but also the full 
translational spectrum from bench to bedside. A direct example of a potential clinical 
application of our observations is the mass spectrometry based analysis of pancreatic 
cyst fluid devised and evaluated in this work. This method detected cystic precursors of 
pancreatic cancer with significantly higher accuracy than state of the art diagnostic 
analyses. Clinical evaluation is currently underway. It will be essential to confirm the 
utility of the method through randomized controlled trials, preferably with patient 
enrolment at different centres. If the analysis is successfully validated, the next 
challenge will be a seamless transition from the university to the hospital laboratories. 
UC is a well described, but poorly understood condition. Better comprehension of the 
underlying mechanisms may enable targeted, individualized treatment that could 
improve patient outcomes. In this thesis, structural weakening of the colonic mucus 
barrier was shown to occur independent of – and likely prior to – inflammation in UC, 
possibly resulting in increased host-bacterial contact and immune cell recruitment. 
These findings may contribute to our understanding of UC pathogenesis, and should be 
explored by further studies. 
Another result that merits follow-up is the potential association between primary 
mucus barrier failure and a reduction in apical chloride-bicarbonate exchanger 
SLC26A3. Our observations provide a possible biological explanation for the previous 
identification of the SLC26A3 gene as a UC risk locus. One way to further investigate 
this association would be to determine whether persistent mucus penetrability is linked 
to altered pH near the epithelium. A more acidic pH, due to reduced bicarbonate 
secretion, would be consistent with defective mucus barrier formation. If confirmed, 
this observation could represent a causative mechanism and putative therapeutic target 
for a subgroup of UC patients. 
While the diagnosis of UC poses relatively few challenges, the natural course is 
heterogeneous, and difficult to prognosticate. This may result in overmedication, as 
well as severe relapses that could potentially have been prevented with more active 
therapeutic measures. Here, we identified the ratio of interacting proteins LRRFIP1 
and FLII as a powerful predictor of frequent relapses and intractable inflammation. 
Still, the prognostic value of these biomarkers will require confirmation by a high-
throughput analysis, using biopsy material or mucus aspirated at colonoscopy. 
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Interestingly, LRRFIP1 and FLII were previously reported to differentially regulate 
TLR4-MYD88 signalling, which is required for the sensing of certain microbial 
ligands. A balance shift in the relative abundances of these proteins, as observed in 
severe colitis, was associated with extensive, mucosal infiltration of bacterial 
endospores. Intuitively, intermittent activation of tissue endospores is compatible with 
the frequent relapses and poor response to immune-modulators observed in this 
subgroup of UC patients. Additional studies are required to validate these findings, 
delineate the mechanisms leading to invasion of spore-forming bacteria, and determine 
the species involved.    
Finally, intestinal spirochetosis was shown to be significantly more common in IBS 
patients, and linked to specific symptoms and mucosal immune responses. This implies 
that Brachyspira-associated IBS represents a large and clinically distinctive subgroup 
that could potentially be responsive to antibiotic therapy. However, the treatment 
regime evaluated in this work did not result in eradication of the infection, instead 
promoting Brachyspira invasion into goblet cells.   
While further treatment studies of IBS patients with concomitant intestinal 
spirochetosis may be clinically motivated at this point, many fundamental issues also 
need to be addressed. One such question concerns the epidemiology of Brachyspira 
colonization. Since the B pilosocoli species also infects several domestic animals, 
zoonotic transmission could be plausible in some cases. However, host susceptibility 
may also contribute to colonization, in ways not yet known. Other important future 
research directions include how Brachyspira penetrates the mucus and attaches to the 
epithelial cells, and the specific type of immune response elicited. Strikingly, the 
relocation of Brachyspira into goblet cell mucus granules appears to represent a novel 
bacterial strategy of persistence during antibiotic therapy. Future studies may identify 
other contexts where this mechanism contributes to recurrent or chronic infections, 
both inside and outside the gut.  
In summary, the results from this thesis may inform the design of clinical trials, as well 
as broad mechanistic investigations. Hopefully, the continued pursuit of these research 
questions will benefit patients with gastrointestinal diseases, both in the short and long 
term 
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